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ABSTRACT. Volumetric modulated arc therapy (VMAT) is a novel radiation technique,
which can achieve highly conformal dose distributions with improved target volume
coverage and sparing of normal tissues compared with conventional radiotherapy
techniques. VMAT also has the potential to offer additional advantages, such as
reduced treatment delivery time compared with conventional static field intensity
modulated radiotherapy (IMRT). The clinical worldwide use of VMAT is increasing
significantly. Currently the majority of published data on VMAT are limited to planning
and feasibility studies, although there is emerging clinical outcome data in several
tumour sites. This article aims to discuss the current use of VMAT techniques in practice
and review the available data from planning and clinical outcome studies in various
tumour sites including prostate, pelvis (lower gastrointestinal, gynaecological), head
and neck, thoracic, central nervous system, breast and other tumour sites.
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There have been significant advances in the delivery of
radiotherapy over the past few decades. These include
increased sophistication of imaging techniques, which
has resulted in improved accuracy of target volume
definition and delineation [1], as well as developments in
treatment planning systems and linear accelerator deliv-
ery capabilities leading to improved dose distributions
and conformity [2]. These developments have been mainly
driven by the need to reduce the dose to normal tissue
structures and thereby minimise the risk of toxicity and
morbidity, which then allows dose escalation to the
tumour volume potentially leading to improved locoregio-
nal control. To that end, newer radiation techniques, e.g.
intensity modulated radiotherapy (IMRT), have been
developed. IMRT techniques employ variable intensity
across multiple radiation beams leading to the con-
struction of highly conformal dose distributions. This is
achieved by subdividing each radiation beam into smaller
radiation beamlets and varying the individual intensities
of these beamlets [3–5]. The advantages of this technique
are improved target volume conformity, particularly in
volumes with complex concave shapes, and improved
sparing of normal tissues and organs at risk (OARs)
resulting in reduced acute and late toxicities [6–9]. IMRT
also has the ability to produce inhomogeneous dose
distributions, which allows the simultaneous delivery of
different doses per fraction to separate areas within the
target volume. This could facilitate localised dose escalation
strategies without increasing total treatment time (for
example, by using hypofractionated regimens), which
may have the potential radiobiological benefit of reducing
the impact of accelerated repopulation in tumour clono-
gens [10, 11].
Despite the obvious benefits of IMRT, there are still
some disadvantages. The planning and quality assurance
(QA) processes required for IMRT are more complex and
time-consuming compared with conventional conformal
radiotherapy (CRT) techniques, which can have signifi-
cant impact on departmental resources [12–15]. However,
several commercial systems are now available that allow
multiple plan measurement of IMRT plans and facilitate
batching of patient QA measurements to improve effi-
ciency. A standard IMRT plan often requires multiple
fixed angle radiation beams, which can increase treatment
delivery time. This can impact on patient comfort on the
treatment couch, reproducibility of treatment position and
intrafraction motion. There are also some concerns that
the increased treatment time could have radiobiological
implications owing to the possibility of increased tumour
cell repair and repopulation during the extra time re-
quired to deliver the treatment [16–18].
IMRT plans use a larger number of monitor units (MU)
compared with conventional CRT plans leading to an
increase in the amount of low dose radiation to the rest of
the body. The number of MU used in fixed field IMRT
depends, to some degree, on the IMRT technique; usually
more MU are required in the sliding window (SW) or
dynamic IMRT technique [19, 20]. In this technique, each
radiation beam is modulated by continuously moving
multileaf collimators (MLCs). This is in contrast to the
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step-and-shoot (SS) or static techniques in which each
beam is subdivided into multiple segments with differing
MLC shapes and the beam is switched off between
segments. The increase in MU and subsequent increase in
low dose radiation has led to concerns of increased risk of
secondary radiation-induced malignancies, which is of
particular relevance in paediatric patients or patients with
long life expectancies [21–23]. There are estimates in the
literature that the number ofMU in an IMRT plan is two to
three times higher than a conventional radiotherapy plan
[21, 24] with an increase in the incidence of radiation-
induced secondary malignancies from 121.75% for patients
who survive for 10 years or more [21].
More recently, there has been some interest in arc-
based or rotational therapies in an attempt to overcome
some of the limitations associated with fixed field IMRT.
The basic concept of arc therapy is the delivery of radia-
tion from a continuous rotation of the radiation source
and allows the patient to be treated from a full 360u beam
angle. Arc therapies have the ability to achieve highly
conformal dose distributions and are essentially an alter-
native form of IMRT. However, a major advantage over
fixed gantry IMRT is the improvement in treatment
delivery efficiency as a result of the reduction in treatment
delivery time and the reduction in MU usage with sub-
sequent reduction of integral radiation dose to the rest of
the body [25–27]. In addition to the subsequent advan-
tages from the shorter treatment delivery time, a further
potential benefit is the availability of extra time within a
set treatment appointment time slot to employ image-
guided radiotherapy (IGRT). IGRT involves the incor-
poration of imaging before and/or during treatment to
enable more precise verification of treatment delivery and
allow for adaptive strategies to improve the accuracy of
treatment [28, 29]. The main drawback of IGRT is the
requirement for more time on the treatment couch and an
increase in the total amount of radiation to the patient,
especially with daily IGRT imaging schedules. These
disadvantages are less of an issue with arc therapies,
which have shorter treatment delivery times and fewer
MU.
There are two main forms of arc-based therapies:
tomotherapy and volumetric modulated arc therapy
(VMAT). Tomotherapy (i.e. ‘‘slice therapy’’) machines
can be considered to be a combination of a CT scanner
and a linear accelerator that can deliver the radiation in a
fan-shaped distribution, similar to CT imaging with a con-
tinuously rotating radiation source, while the patient is
moved through the machine. Tomotherapy techniques can
be subdivided into axial or serial tomotherapy (where the
radiation is delivered slice by slice) or helical tomotherapy
(HT) (where the radiation is delivered in a continuous
spiral) [30–33]. There is limited data on axial tomotherapy
in comparison with fixed field IMRT. HT has been
evaluated in a variety of tumour sites and it can generally
achieve either similar or improved dose distributions
compared with fixed field IMRT, with variable results on
treatment time comparisons [34–40]. The details of these
studies and a review of the use of HT have been discussed
elsewhere [25] and will not be discussed in detail in this
paper.
VMAT was first introduced in 2007 and described as a
novel radiation technique that allowed the simultaneous
variation of three parameters during treatment delivery,
i.e. gantry rotation speed, treatment aperture shape via
movement of MLC leaves and dose rate [41]. The earlier
form of arc therapy, termed intensity modulated arc
therapy (IMAT) was first described by Yu in 1995 [26]
and required the use of multiple superimposed arcs to
achieve a satisfactory dose distribution [42]. More recent
VMAT techniques have allowed the whole target volume
to be treated using one or two arcs, although complex
cases may require more. In a recent review, VMAT is
essentially described as a form of single arc IMAT tech-
nique that employs dose rate variation [43]. One benefit of
VMAT compared with tomotherapy is the possibility of
delivering this treatment on conventional linear accel-
erators, which are configured to have this capability.
Currently there are several VMAT systems available under
various names (RapidArc, Varian; SmartArc, Phillips; and
Elekta VMAT, Elekta). The main aim of this review is to
discuss the current use of VMAT techniques in practice,
and review the available data from planning studies and
the clinical outcomes in various tumour sites. A second
aim is to identify future areas for research in this field.
A systematic review was conducted using PubMed/
MEDLINE with the keywords ‘‘volumetric’’ and ‘‘arc’’.
165 articles were identified of which 65 were relevant for
the purpose of this review.
Prostate cancer
Prostate cancer is one of the most common tumour sites
treated with IMRT worldwide. The use of IMRT allows
dose escalation, which has been shown to improve clinical
outcomes while simultaneously reducing toxicity by
improved OAR sparing [8, 44–50]. As a result, IMRT is
now the standard technique employed for primary prostate
radiotherapy at several institutions. Therefore, this is a
logical starting point for the evaluation of alternative IMRT
techniques, such as VMAT. One of the earliest VMAT
planning studies was performed by Palma et al [51] in
which a planning comparison was performed in 10 patient
datasets between standard three-dimensional (3D)-CRT,
fixed field IMRT using 5 coplanar fields (SW), constant
dose rate-VMAT (CDR-VMAT) and variable dose rate-
VMAT (VDR-VMAT). The results report significantly
improved OAR sparing with both IMRT and VMAT plans
compared with 3D-CRT, with acceptable planning target
volume (PTV) coverage. The lowest doses to the OARs
were achieved in the VDR-VMAT plans, which required
42% fewer MU compared with the fixed field IMRT plans.
The improved OAR sparing with VMAT has been
reported in other planning studies. A planning study of
11 prostate cancer patients at Memorial Sloan Kettering
Cancer Centre compared 5-field fixed field IMRT (SS)
with VMAT [52]. They report improved rectal wall
sparing with a resultant improved Normal Tissue Com-
plication Probability (NTCP) of rectal wall by 1.5%, and
lower doses to the bladder wall (not statistically sig-
nificant) and femoral heads. Similar findings were seen in
a Danish study comparing single partial arc VMAT with
fixed field IMRT (SW) which showed improved bladder
and rectal sparing [53]. Hardcastle et al [54] also found
lower doses to the rectum with resultant lower rectal
NTCP in their study comparing VMAT to seven-field
fixed field IMRT (SS). Ost et al [55] compared fixed field
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IMRT (SS) with VMAT for prostate radiotherapy with a
simultaneous integrated dose-escalated boost to intrapro-
static lesions defined with MRI with or without magnetic
resonance spectroscopy. In this study, fixed field IMRT
plans using 3 fields, 5 fields and 7 fields were generated
for each of the 12 patient datasets. Compared with all
three, the VMAT plans performed better in reducing the
dose to the rectum which was statistically significant in
the volumes receiving doses between 20 Gy and 50 Gy
(e.g.V50 Gywas 45% in the 7-field IMRT vs 32% in VMAT,
p50.001). Another study by Weber et al [56] compared
5-field IMRT (SW) with intensity modulated proton
therapy (IMPT) and VMAT for recurrent prostate can-
cer previously treated with radiotherapy and found
improved OAR sparing with IMPT and VMAT compared
with IMRT. More recently a large study of 292 patient
datasets comparing VMAT and 7-field fixed field IMRT
(SW) showed that VMAT could achieve lower mean doses
to the bladder and rectum, particularly in the high dose
regions [57].
However, other planning studies have reported con-
tradictory results in terms of OAR sparing. Yoo et al [58]
performed a planning study comparing fixed field IMRT
using 7 coplanar fields to single and double arc VMAT in
10 patients with high risk prostate cancer and reported
lower mean doses to the OARs in the IMRT plans. For
instance the mean dose to the rectum was 35.5 Gy in the
IMRT plan compared with 40.2 Gy in the single arc and
37.5 Gy in the double arc VMAT plans. The differences
were statistically significant for rectal and small bowel
doses. Another study by Wolff et al [59] which compared
VMAT with serial tomotherapy, fixed field IMRT (SS)
and 3D-CRT found lower mean doses to the rectum with
tomotherapy and IMRT compared with VMAT plans.
Tsai et al [60] compared VMAT with fixed field IMRT
(SS) and HT and found superior dose conformity and
OAR sparing with HT. A similar planning study by Rao
et al [61] comparing VMAT with HT and fixed field
IMRT (SS) found largely equivalent sparing of OARs
between the three techniques (although maximum dose
to the femoral head was lower by an average of 1.3 Gy in
the VMAT plans compared with HT).
Overall, most of these planning studies have reported
comparable and acceptable PTV coverage with VMAT
techniques compared with fixed field IMRT. The results
on target volume homogeneity and conformity are more
conflicting, with some studies reporting improved con-
formity and/or homogeneity with VMAT [58, 61] while
others reported better results with fixed field IMRT [59,
64]. This variation could be due to a number of factors
including the number of arcs used in the VMAT plans (in
general, double arc plans can achieve higher conformity
and homogeneity compared with single arc plans), the
type of VMAT optimisation approach and the number of
fields used in the fixed field IMRT plans. Generally, better
quality IMRT plans can be obtainedwith larger number of
fields and this could explain the better results with fixed
field IMRT found in the studies by Yoo et al [58] andWolff
et al [59]. However, it is worth bearing in mind that
many institutions have adopted a five-field technique
over seven- or nine-fields as their class solution for
prostate IMRT because of greater efficiency and ease of
treatment delivery and verification. Another difficulty in
analysing these planning studies is the differences in
target volume definition and dose prescriptions. For
example, some studies have defined their primary plan-
ning target volume (PTV) as the prostate or prostate and
seminal vesicles only [52, 59] while in the study by Yoo
et al [58], the primary PTV was larger because the pelvic
lymph nodes were included in the target volume. Dose
prescriptions also varied with some studies also evaluat-
ing the feasibility of dose escalation [62, 64]. Shaffer et al
[62] evaluated the simultaneous integrated boost (SIB)
technique with a boost to intraprostatic lesions (up to
88.8 Gy) and found improved coverage of the boost
region with VMAT compared with fixed field IMRT (SW)
with acceptable doses to the OARs.
One of the major concerns with any IMRT technique is
the potential increased risk of radiation-induced second-
ary malignancy. In most studies, the volume of normal
tissue receiving radiation dose is defined as the integral
dose, which is proportional to the product of dose
multiplied by the number of voxels for unit density. This
is dependent on a number of factors including the
number of MU, which is associated with scattered and
leakage radiation from the linear accelerator. In these
planning studies, VMAT plans generally use fewer MU
(up to 65% fewer) compared with fixed field IMRT
[52, 53, 58]. However, the results on integral dose are
more varied. Some studies have reported no difference
in integral doses between VMAT and IMRT [53, 55],
while others report a higher integral dose with VMAT
compared with IMRT [58]. Yoo et al [58] have reported
that a possible reason for this discrepancy is that integral
dose is dependent not only on MU, but also on target
volume and aperture size and shape. It is worth noting
that the dose distribution obtained in VMAT plans
generally show an increase in the volume of the area
receiving low dose radiation compared with fixed field
IMRT due to the spread of dose from the entire arc of
360u. In a study by Zhang et al [52] normal tissue doses in
VMAT plans were reported as lower in the intermediate
to high dose levels (28–48 Gy), but higher in the low dose
levels (below 22 Gy) compared with fixed field IMRT.
An argument for the use of IMRT techniques, including
VMAT, is the increase in conformity with the resultant
reduced higher dose to normal tissues outside the target
volume, which may in fact compensate for the increased
low dose radiation [63].
A common finding from these planning studies is the
improved efficiency of VMAT delivery with a reduction
in treatment delivery times [52, 58–60]. A single arc
VMAT treatment fraction can potentially be delivered in
1–1.5 min compared with 5–10 min with a 5- or 7-field
IMRT fraction. The potential benefits of faster treatment
times have already been discussed above. The issue of
intrafraction motion may be of particular relevance in
prostate radiotherapy as there may be significant changes
in rectal and bladder volumes within the time period
required to deliver an IMRT fraction. This could poten-
tially compromise target volume coverage and reduce
tumour local control. In addition, the use of hypofractio-
nated treatments that use larger doses per fraction is
becoming increasingly common, particularly in prostate
cancer, which is estimated to have a lower a/b ratio than
other tumours and therefore theoretically could benefit
more from hypofractionated schedules [65–68]. The impact
of this change in treatment schedules is increasedMU and
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treatment time per fraction where faster VMAT delivery
techniques may be an attractive solution. It is worth
noting that the optimisation and dose calculation times
for VMAT planning are longer compared with fixed
field IMRT (up to 64) [58]. However, VMAT tech-
nology is still developing and newer versions of the
planning algorithm software as well as increasing exper-
ience and expertise may well speed up the optimisation
and planning process.
Few studies have reported clinical outcome data
because of the novelty of VMAT technology. Pesce et al
[69] reported their results on 45 patients treated with
VMAT (RapidArc, Varian) in their institution. In terms of
acute toxicity (graded by the National Cancer Institute
Common Terminology Criteria of Adverse Effects (NCI
CTCAE) version 3), there was no acute Grade 2 or 3
rectal toxicity reported while 12% of patients experi-
enced Grade 2 dysuria and 44% had preserved erectile
function. Biochemical response recorded at 6weeks showed
median PSA levels reduced to 0.4. Further follow-up will
be required to evaluate clinical outcome such as local
control and survival as well as late toxicity parameters.
The issue of secondary malignancy induction will be of
particular interest given that it is still too early to quantify
this risk accurately for IMRT and VMAT techniques.
A summary of the comparative planning studies
evaluating VMAT in prostate cancer is presented in
Table 1. An example of the dose distributions achieved
with VMAT and fixed field IMRT for prostate cancer is
illustrated in Figure 1.
Pelvic malignancies (lower gastrointestinal,
gynaecological cancers)
Given the success of IMRT in prostate cancer, there has
been interest in the use of these techniques in the treat-
ment of other pelvic malignancies including lower
gastrointestinal and gynaecological cancers. Conventional
fixed field IMRT has been evaluated in anal and rectal
cancer as well as cervix and endometrial cancers [70–74].
In general the results are positive with improved dose
conformity and sparing of OARs seen with IMRT com-
pared with conventional conformal radiotherapy.
Anal cancer
Several planning studies have evaluated VMAT in anal
cancer. Clivio et al [75] conducted a planning study in 10
patients with Stage T2–4 N0/+ anal cancer comparing
fixed field IMRT (7–9 fields, SW) with single and double
arc VMAT. The results showed that PTV coverage was
largely similar between the techniques, although double
arc VMAT achieved slightly better coverage and dose
homogeneity compared with IMRT while single arc was
slightly inferior. For the primary tumour (PTV1), the dose
received by 98% of the volume (D98%) was 95.9% in the
double arc compared with 94.6% in the IMRT plan (this
was statistically significant). IMRT was slightly superior
in dose conformity (not statistically significant). Re-
garding OAR sparing, double arc VMAT plans reduced
the volume of bladder treated to medium-low radiation
dose levels (10–40 Gy) and significantly reduced mean
doses to the femora. Doses to the small bowel and healthy
tissue were not significantly different between the two
techniques. Double arc VMAT allowed more sparing of
the male external genitalia (testis and penile bulb)
compared with IMRT and single arc VMAT.
Following this study, two other planning comparison
studies for anal cancer were recently conducted. Vieillot
et al [76] compared seven-field fixed field IMRT (SW)
with single and double arc VMAT and found similar
results to Clivio’s study [75] with equivalent PTV
coverage, dose homogeneity and conformity (double
arc VMAT performed slightly better in conformity, but
this was not statistically significant) and improved OAR
sparing with double arc VMAT. Following the results of
an initial evaluation comparing single and double arc
VMAT, Stieler et al [77] then compared double arc
VMAT with conventional CRT and nine-field fixed field
IMRT (SS). Again the results showed largely similar PTV
coverage with CRT showing the most homogeneous but
least conformal dose distribution and IMRT achieving
higher conformity compared with VMAT. They also
reported that IMRT produced the best sparing of non-
PTV healthy tissue with no significant difference in
bladder and small bowel doses.
Direct comparisons between these planning studies
are difficult due to the inherent differences in patient
population, target volume delineation, dose prescrip-
tions and planning techniques, which can all introduce
bias. In particular, Clivio et al [75] discuss the paucity of
data for conventional IMRT in anal cancer, which has
made it difficult to set realistic dose constraints for
OARs in the optimisation process. In fact, the OAR doses
in their study were lower than those seen in previous
IMRT studies, although a direct comparison without
bias is not possible. A significant reduction in MU (of up
to 70%) and treatment time was reported in these studies
[75–78]. Although double arc VMAT used more MU
than single arc, this was still considerably less than in
the IMRT plans and would be the preferred option
considering the better target coverage, homogeneity and
OAR sparing.
Rectal cancer
Arc therapy was initially evaluated in rectal cancer
by Duthoy et al [78] in a planning study comparing
3D-CRT and IMAT (3–6 arcs). They found similar PTV
coverage, but significantly lower mean doses to small
bowel and integral dose in the IMAT plans. Richetti et al
[79] reported on their technical and clinical experience
of 25 patients with locally advanced rectal cancer treated
with VMAT and performed a planning comparison with
a matched cohort of patients who underwent conven-
tional conformal radiotherapy. Although PTV coverage
was similar, single arc VMAT achieved significantly
superior dose conformity with a trend to improvement
in homogeneity and improved OAR sparing (small
bowel, femora and healthy tissue). In terms of acute
toxicity, up to 50% of patients had diarrhoea and 8% of
patients who received VMAT experienced NCI CTCAE
v3.0 Grade 3 bowel toxicity. Longer follow-up is re-
quired to assess the clinical outcome and late toxicity
following VMAT.
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Table 1. Comparative planning studies in prostate cancer
Paper [ref] VMAT
commercial system
Number of
patients
Site and dose Comparison PTV OAR MU per fraction Treatment time
per fraction
Palma et al [51]
Predecessor
to RapidArc
10 Prostate alone
74 Gy in 37
fractions
3D-CRT vs
IMRT(5F,SW) vs
CDR-VMAT
(SA)
vs VDR-VMAT
(SA)
IMRT and VMAT – similar PTV
coverage and homogeneity
(homogeneity inferior to
3D-CRT). Conformity best
with IMRT and VDR-VMAT
VDR-VMAT best (compared
with IMRT for sparing of
rectum and femoral heads;
compared with CDR-VMAT
for sparing of bladder
and rectum)
CDR-VMAT, 491.6;
VDR-VMAT, 454.2;
IMRT, 788.8;
3D-CRT, 295.5
Zhang et al [52] 11 Prostate + prox
imal SV
86.4 Gy
IMRT (5F,SS) vs
VMAT (SA)
IMRT – slightly higher dose to
PTV (V95%, D95%, mean
dose and TCP) and better
homogeneity compared
with VMAT
VMAT better then IMRT
(sparing of rectum,
bladder, femoral heads)
VMAT, 290; IMRT,
642
VMAT, 1 min;
IMRT, 5 min
Kjaer-
Kristoffersen
et al [53]
RapidArc
8 Prostate + SV,
78 Gy (5 pts);
74 Gy (1 pt)
Prostate bed,
66 Gy (2 pts)
IMRT (5F,SW) vs
VMAT (partial
SA)
IMRT – slightly better PTV
coverage (V95%) but VMAT
better in PTV minus rectum
coverage. Hotspots higher
in VMAT plans.
VMAT better than IMRT
(sparing of bladder, rectum).
Integral dose to body
similar. Low dose bath
(V5 Gy) to body larger
for VMAT
VMAT, 529; IMRT,
647
Hardcastle et al
[54] SmartArc
10 Prostate 78 Gy
in 39 fractions
IMRT (7F,SS) vs
VMAT (SA)
IMRT and VMAT 2 similar
PTV coverage (except
D95% where VMAT had
lower values).
VMAT better than IMRT at
rectal sparing at doses
,50 Gy. VMAT – higher
doses to femoral heads. No
significant difference in
bladder doses.
VMAT, 417; IMRT,
526
VMAT, 1.3 min;
IMRT, 4.5 min
Ost et al [55] 12 Prostate + SV
(76 Gy) and IPL
boost (82 Gy).
Additional IPL
dose level.85 Gy
IMRT
(3F,5F,7F,SS)
vs VMAT (SA)
IMRT (5F,7F) and VMAT –
similar PTV coverage and
all better than IMRT 3F.
Dose escalation up to 95
Gy to IPL with VMAT
VMAT better at rectal
sparing (significant at
rectal volumes receiving
20250 Gy). No difference
in integral dose to body.
For 6 MV: VMAT,
447; IMRT (3F),
362; IMRT (5F),
407; IMRT (7F),
434
VMAT, 1.95 min;
IMRT (5F),
3.85 min; IMRT
(7F), 4.82 min
Weber et al
[56] RapidArc
7 Recurrent
prostate carci
noma 56 Gy
in 14 fractions
IMRT (5F,SW) vs
IMPT vs VMAT
(SA)
IMPT best for PTV coverage,
VMAT better than IMRT for
GTV and PTV coverage.
VMAT (high definition MLC)
– best for homogeneity.
IMRT, VMAT better than
IMPT for conformity
IMPT and RA better than
IMRT (sparing of rectum,
urethra, bladder). Integral
doses to body lowest
with IMPT. IMPT best
at sparing penile bulb
Kopp et al
[57] RapidArc
292 Prostate 77.4 Gy
in 43 fraction
IMRT (7F,SW) vs
VMAT (SA)
VMAT and IMRT similar PTV
coverage (VMAT less
homogeneous). VMAT –
slightly higher D2%
VMAT better than IMRT
(sparing of rectum at
high doses, bladder,
femoral heads, penile bulb)
Yoo et al
[58] RapidArc
10 Prostate, SV and
LN (primary)
46.8 Gy; prostate
and SV
(boost) 28.8 Gy
(1.8 Gy per
fraction)
IMRT (9F,7F) vs
VMAT (SA) vs
VMAT (DA)
Primary plans – IMRT better
than VMAT (PTV coverage,
conformity). Boost plans –
similar PTV coverage,
homogeneity; IMRT had
worse conformity compared
to VMAT
Primary plans-IMRT better
than VMAT (sparing of
bladder, rectum, small
bowel). Boost plans – IMRT
and DA VMAT better than
SA VMAT. Higher integral
doses to body with VMAT
Primary plans:
VMAT (SA), 429;
(DA), 444; IMRT,
1300. Boost
plans: VMAT (SA),
443; VMAT (DA),
484; IMRT, 777
Primary plans: VMAT
(SA), 1.5 min; VMAT
(DA), 3.1 min; IMRT,
8.1 min. Boost plans:
VMAT (SA), 1.5 min;
VMAT (DA), 3.1 min;
IMRT, 4.9 min.
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Paper [ref] VMAT
commercial system
Number of
patients
Site and dose Comparison PTV OAR MU per fraction Treatment time
per fraction
Wolff et al
[59] ERGO++
9 Prostate + SV
76 Gy
3D-CRT vs IMRT
(7F,SS) vs VMAT
(SA,DA) vs ST
VMAT and ST2 better PTV
coverage compared with
IMRT. Conformity better
with IMRT. No difference
in homogeneity
ST and IMRT better
than VMAT for rectal
sparing
VMAT (SA), 386;
VMAT (DA), 371;
IMRT, 544;
ST, 2714
VMAT (SA),
1.8 min; VMAT
(DA), 3.7 min;
IMRT, 6 min;
ST, 12 min.
Tsai et al
[60] ERGO++
12 Prostate ¡ SV
78 Gy in 39
fraction
IMRT (5F,SS) vs
VMAT (SA) vs
HT
Similar PTV coverage between
all three techniques. HT –
better conformity
HT better than VMAT
and IMRT at rectal
sparing at 65 Gy and 40
Gy (VMAT slightly better
than IMRT). No difference
in bladder and femoral
head sparing.
VMAT, 309.7;
IMRT, 336.1;
HT, 3368
VMAT, 2.6 min;
IMRT, 3.8 min;
HT, 3.8 min
Rao et al
[61] SmartArc
6 (of 18) Not specified IMRT (7F,SS) vs
VMAT (SA) vs
HT
Similar PTV coverage between
all three techniques.
VMAT – slightly better
homogeneity.
No significant difference
between all three
techniques VMAT –
slightly lower maximum
dose to femoral heads
compared with HT
and IMRT.
VMAT, 549;
IMRT, 639
VMAT, 2.2 min;
IMRT, 8.1 min;
HT, 4.0 min
Shaffer et al
[62]
Predecessor
to RapidArc
10 Prostate 74 Gy
in 37 fractions
+ SIB to pros
tate CTV up
to 88.8 Gy
IMRT (9F,SW) vs
VMAT (SA)
Volume of CTV boosted and
mean dose within boost
region higher with VMAT
VMAT, 949;
IMRT, 1819
VMAT, 3.7 min;
IMRT, 9.6 min
Crijns et al
[64] RapidArc
11 Prostate + SV
(SIB) 74 Gy
+ 55 Gy in
37 fractions
IMRT vs VMAT
(SA)
No significant difference
in PTV coverage (small
differences depending
on VMAT optimisation
approach).
IMRT – better homogeneity
No significant differences
(except rectal maximum
doses lower in some VMAT
optimisation approaches).
Mean rectal NTCP lower
in VMAT
VMAT,
1.221.5 min
Guckenberger
et al [94]
SmartArc
5 (of 20) Prostate + SV
(SIB) 74 Gy
+ 60 Gy in
33 fractions
IMRT (7F,SS) vs
VMAT (SA) vs
VMAT (DA)
Similar PTV coverage (slightly
better with DA VMAT).
VMAT – better conformity
VMAT slightly better than
IMRT at rectal, bladder
sparing (except rectal
V70 Gy which is higher
with VMAT)
VMAT (SA), 465;
VMAT (DA), 572;
IMRT, 513
VMAT (SA),
2.08 min;
VMAT (DA),
3.87 min; IMRT,
5.82 min
VMAT, volumetric modulated arc therapy; PTV, planning target volume; OAR, organs at risk; MU, monitor units; Gy, Gray; 3D-CRT, three-dimensional conformal radiotherapy; IMRT,
intensity modulated radiotherapy; CDR, constant dose rate; VDR, variable dose rate; 5F, five field; 7F, seven field; 9F, nine field; SW, sliding window; SS, step-and-shoot; SA, single
arc; DA, double arc; SV, seminal vesicles; V95%, volume receiving>95% prescribed dose; D95%, dose to 95% of volume; TCP, tumour control probability; V5 Gy, volume receiving
>5 Gy; IPL, intraprostatic lesion; MV, megavoltage; IMPT, intensity modulated proton therapy; MLC, multileaf collimator; D2%, dose to 2% of volume; ST, serial tomotherapy; HT,
helical tomotherapy; SIB, simultaneous integrated boost; CTV, clinical target volume; V70 Gy, volume receiving >70 Gy.
Table 1. Continued
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Gynaecological cancer
For gynaecological cancers, IMAT was one of the first
arc techniques evaluated for whole abdominopelvic
radiotherapy (WAPRT) in the treatment of relapsed
ovarian cancer [80]. This technique was also used in the
study by Wong et al [81] to investigate patients with
high risk endometrial cancer. Both studies have reported
acceptable target volume coverage and OAR sparing
that was similar to fixed field IMRT and superior to
conventional techniques. Whereas multiple arcs were used
in the Ghent study, Wong et al [81] reported that two
anterior arcs were sufficient in treating the target volume
adequately with acceptable sparing of OARs. VMAT has
been evaluated as a next logical step given the possibility of
treating the entire target volume in a single arc, which
would reduce treatment delivery time.
Cozzi et al [82] conducted a planning study comparing
VMAT with five-field conventional fixed field IMRT
(SW) in eight patients with cervical cancer. The results
show similar target volume coverage with improved
homogeneity and conformity with VMAT. OAR sparing
(bladder and rectum) was significantly improved with
VMAT with lower mean doses and volume that received
at least 40 Gy (V40 Gy). For the rectum, mean dose and
V40 Gy in the VMAT plans were 36.3 Gy and 51.5%,
respectively, compared with 42.5 Gy and 78.7% in the
IMRT plans. A similar trend was found with small bowel
sparing. This resulted in a potential relative reduction in
NTCP estimates for rectal bleeding, bladder contracture/
loss of volume and small bowel obstruction/perforation
by 30–70%. Integral dose to healthy tissue was also
reduced with VMAT by an average of 12% compared
with IMRT. The superior results seen with VMAT in this
study appear more pronounced compared with the
previously mentioned studies for anal and rectal cancer,
although direct comparisons are difficult given the
numerous biases, for example, the difference in target
volume size and definition (the PTV in anal cancer
patients included the pelvic and inguinal nodes, while
this study only included the pelvic nodes). Another
possible explanation is that in Cozzi et al’s study [82] the
IMRT plans were optimised using five coplanar fields
while the other studies used between seven- and nine-
fields. The increase in the number of fields could have
improved the quality of the IMRT plans leading to less
pronounced differences with the VMAT plans, but at the
expense of higher MU and longer treatment times. While
it is clear that IMRT techniques are superior to conven-
tional CRT, it is less certain how IMRT compares with
intracavitary brachytherapy. Brachytherapy has the
advantage of organ immobilisation with very steep dose
gradients and highly conformal dose distributions,
which are not currently matched by IMRT techniques;
therefore, the general consensus is that IMRT or VMAT
will not replace the role of brachytherapy in gynaecolo-
gical cancers [7].
The use of WAPRT for ovarian cancer is not con-
sidered standard practice in the UK. This is despite
some studies reporting response rates and outcomes for
(a) (b)
(c) (d)
Figure 1. Example of dose distributions in (a,b) IMRT and (c,d) VMAT plans for radiotherapy to prostate (primary planning
target volume (PTV)) and pelvic lymph nodes (elective PTV). The dose prescribed to the primary PTV and elective PTV is 74 Gy and
55 Gy in 37 fractions, respectively. The primary PTV (red contour) is encompassed by the 95% isodose (orange line and colour
wash) and the elective PTV (pink contour) is encompassed by the 70.6% isodose (dark blue line and light green colour wash).
Some sparing of the rectum (brown contour) and bladder (yellow contour) is achieved. Figures courtesy of Department of
Medical Physics, Royal Surrey County Hospital, UK.
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WAPRT that are comparable with chemotherapy in the
palliative and adjuvant setting [83–85]. One of the main
concerns with WAPRT is the risk of increased toxicity
due to irradiation of critical structures and normal tissues,
which can limit the dose and coverage of the target
volume. IMRT techniques may allow the facilitation of
this approach by improved conformity, OAR sparing and
the feasibility of dose escalation [86]. A recent planning
study by Mahanshetty et al [87] compared double arc
VMAT with fixed field IMRT (SW) in five patients
undergoing WAPRT as consolidation therapy following
treatment with surgery and chemotherapy. Both techni-
ques were largely similar in terms of target coverage,
homogeneity and OAR sparing, although IMRT was
slightly better in sparing the volume of bladder and liver
outside the PTV for doses over 20 Gy. Another study by
Matsuzak et al [88] comparing VMAT with IMRT for
WAPRT showed acceptable PTV coverage for both tech-
niques, but slightly superior bone marrow sparing with
VMAT (mean dose 19.8 Gy vs 21.9 Gy). Both studies
found reducedMU use and treatment delivery times with
VMAT compared with fixed field IMRT. The shortened
treatment time may reduce the impact of intrafraction
motion, which may be significant in intra-abdominal
radiotherapy.
A summary of the comparative planning studies
evaluating VMAT in pelvic malignancies (lower gastro-
intestinal and gynaecological cancer) is presented in
Table 2.
Head and neck cancer
Radiotherapy for head and neck cancer can be
challenging due to the complex anatomy of the head
and neck region with these tumours often located within
close proximity to critical structures which can limit
radiation dose. In addition, these tumours often display
an aggressive phenotype and often grow rapidly due to
the rich lymphatic supply in the head and neck region,
and can therefore present at a locally advanced stage.
Radiotherapy is an important treatment modality in these
tumours as it offers an alternative treatment option to
surgical resection which can cause unacceptable cosmetic
disfigurement and functional impairment. Randomised
evidence has shown that IMRT can reduce late toxicity
parameters such as xerostomia by increasing sparing of
the parotid glands [89]. Furthermore the ability of IMRT
to produce inhomogeneous dose distributions can be
exploited to simultaneously treat the primary and elective
target volumes (areas at risk of microscopic spread of
disease) to different dose per fractions without increasing
overall treatment time. This SIB technique allows both
volumes to be treated within one treatment plan without
the need for matching fields therefore reducing the
potential risk of reduced dose coverage in the areas of
matching beams [90].
Several planning studies have compared dosimetric
results achieved with VMAT plans with fixed field IMRT
plans. Verbakel et al [91] compared single and double arc
VMAT with 7-field fixed field IMRT (SW) in 12 patients
with advanced tumours of the nasopharynx, oropharynx
and hypopharynx. The PTV coverage was similar be-
tween IMRT and VMAT with improved homogeneity
when using two arcs with VMAT. Similarly there were
no significant differences in the doses to the OARs,
although the authors report a slightly lower mean dose
(average of 2 Gy) to the parotid glands with the double
arc VMAT plans compared with the single arc and IMRT
plans. The results in this study were relatively similar to
a larger planning study by Vanetti et al [92] which
compared single and double arc VMAT with 7–9 field
fixed field IMRT (SW) in 29 patients with tumours of the
oropharynx, hypopharynx and larynx. PTV coverage and
conformity were similar in the two groups with better
homogeneity in the double arc VMAT plans. In this
study, the mean doses to the OARs were lower in the
VMAT plans with double arc plans achieving signifi-
cantly lower doses compared with single arc plans. For
the spinal cord, the D2% was 39 Gy in the double arc
VMAT plans and 42.8 Gy in the IMRT plans. For the
brainstem D2% was 23.8 Gy for double arc VMAT and
38.2 Gy for IMRT. For the contralateral parotid glands,
the mean dose was 28.2 Gy for double arc VMAT and
32.6 Gy for IMRT, while for the ipsilateral glands the
mean dose was 34.4 Gy and 40.1 Gy for the double arc
VMAT and IMRT plans, respectively. Additional OARs,
including cochlea, vocal apparatus and oesophageal
constrictors, were also defined and evaluated in this
study; however, no specific dose constraints were set for
these. Again there was greater sparing of these OARs
with the VMAT plans achieving lower mean doses to
these structures. Integral doses to the body were also
lower in the VMAT plans by an average of 7% com-
pared with the fixed field IMRT plans. A more recent
planning study comparing VMAT with fixed field IMRT
(SW) in nasopharyngeal and oropharyngeal cancer con-
firmed improved sparing of the contralateral parotid
glands with comparable PTV coverage between the two
techniques [93].
The number of arcs to use in VMAT plans has already
been discussed. Owing to the complexity of the target
volumes in head and neck radiotherapy, the general
consensus is that more than one arc is required to
achieve an acceptable dose distribution. Guckenberger
et al [94] conducted a planning study that included pa-
tients receiving primary or post-operative radiotherapy
for pharyngeal tumours (10 patients) and 5 patients with
paranasal sinus tumours. Each patient had a nine-field
fixed field IMRT plan (SS) and a single arc, double
arc and triple arc VMAT plan. In the post-operative
pharyngeal patients, PTV coverage was inferior in the
single arc VMAT plan compared with the IMRT plan.
The double arc plan was equivalent to IMRT and triple
arc was superior in terms of PTV coverage and
homogeneity. In primary pharyngeal patients, both
single arc and double arc VMAT plans were inferior to
the IMRT plan, while the triple arc plan was equivalent.
In the paranasal sinus group, all VMAT plans were
inferior to the IMRT plan for dose coverage, particularly
in the region between the orbits. The mean dose to the
lenses in this group was also higher in the VMAT plans
compared with the IMRT plans. The superiority of
double arc VMAT plans compared with single arc in
terms of PTV coverage and OAR sparing was also
confirmed in other planning studies [88, 89, 96].
However, another study by Bertelsen et al [95] that
compared single arc VMAT plans with fixed field IMRT
M Teoh, C H Clark, K Wood et al
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Table 2. Comparative planning studies in pelvic malignancies (lower gastrointestinal, gynaecological)
Paper [ref] VMAT
commercial system
Number of
patients
Site Comparison PTV OAR MU per fraction Treatment time per
fraction
Clivio et al
[75] RapidArc
10 Anal IMRT (729F, SW) vs
VMAT (SA) vs
VMAT (DA)
Similar PTV coverage and
homogeneity (DA
VMAT slightly better than
SA VMAT and IMRT; SA
VMAT slightly inferior to
IMRT). No significant
difference in conformity
VMAT better than IMRT at sparing
bladder at medium-low dose levels
(lower V30 Gy) and femora. No
difference in small bowel sparing.
DA VMAT better than SA VMAT and
IMRT at sparing male external
genitalia. No difference in
healthy tissue doses.
IMRT, 1531;
VMAT (SA),
468; VMAT
(DA), 545
IMRT, 9.4 min;
VMAT (SA),
1.1 min;
VMAT (DA),
2.6 min
Vieillot et al
[76] RapidArc
10 Anal IMRT (7F,SW) vs
VMAT (SA) vs
VMAT (DA)
Similar PTV coverage. DA
VMAT and IMRT similar in
conformity and homogeneity
(both better than SA VMAT)
DA VMAT better than IMRT and
SA VMAT at sparing bladder and
external genitalia at medium-low
dose levels and lower mean doses
to small bowel and femoral heads.
No difference in healthy tissue doses
IMRT, 1646;
VMAT (SA),
330; VMAT
(DA), 493
IMRT, 14 min;
VMAT (SA),
1.1 min;
VMAT (DA),
2.3 min
Stieler et al
[77] ERGO++
8 Anal 3D-CRT vs IMRT
(9F,SS) vs
VMAT (DA)
Similar PTV coverage. 3D-CRT
– best homogeneity but
worst conformity. IMRT
slightly better than VMAT
for conformity
IMRT better than VMAT at sparing
non-PTV tissue. IMRT and VMAT
better than 3D-CRT for bladder
sparing. No significant differences
between IMRT and VMAT for
bladder and bowel sparing
IMRT, 47721260;
VMAT, 268;
3D-CRT, 225
IMRT,
9.5210.3 min;
VMAT,
4.8 min;
3D-CRT,
3.7 min
Richetti et al
[79] RapidArc
25 Rectal 3D-CRT (3F) vs
VMAT (SA)
(matched cohort
of 20 patients
treated with
3D-CRT)
Similar PTV coverage. VMAT
significantly better than
3D-CRT for conformity (with
trend to improvement in
homogeneity)
No significant difference in bladder
sparing (although bladder volumes
were different). VMAT better than
3D-CRT at sparing femora and
bowels. VMAT – lower integral
mean dose to body
VMAT, 276;
3D-CRT, 293
VMAT, 2.05 min;
3D-CRT,
3.42 min
Cozzi et al
[82] RapidArc
8 Cervix IMRT (5F,SW) vs
VMAT
VMAT better than IMRT for
conformity and slightly
better for PTV coverage
and homogeneity
VMAT significantly better than IMRT
at bladder and rectal sparing (similar
trend with small bowel sparing).
VMAT – 12% lower integral dose
to body compared with IMRT
IMRT, 479;
VMAT, 245
IMRT, 15 min;
VMAT,
1.022.3 min
Mahanshetty
et al [87]
RapidArc
5 WAPRT for
ovarian
cancer
IMRT (7F,SW) vs
VMAT (TA, two
full and one
partial
anterior arc)
Similar PTV coverage. VMAT
and IMRT (15MV) better
conformity compared
with IMRT (6MV)
No significant differences. 15MV slightly
better than 6MV (both IMRT and
VMAT). IMRT (15MV) slightly better
than VMAT (15MV) at sparing bladder
minus PTV and liver for doses higher
than 20 Gy
IMRT, 28412
3103; VMAT,
5382635
IMRT,
17.4218 min;
VMAT, 4.8 min
VMAT, volumetric modulated arc therapy; PTV, planning target volume; OAR, organs at risk; MU, monitor units; IMRT, intensity modulated radiotherapy; 3F, three field; 5F, five
field; 7F, seven field; 9F, nine field; SW, sliding window; SS, step-and-shoot; SA, single arc; DA, double arc; Gy, Gray; V30 Gy, volume receiving >30 Gy; 3DCRT, three-dimensional
conformal radiotherapy; TA, triple arc; MV, megavoltage; WAPRT, whole abdominopelvic radiotherapy.
R
e
vie
w
a
rticle
:
A
re
vie
w
o
f
vo
lu
m
e
tric
m
o
d
u
la
te
d
a
rc
th
e
ra
p
y
T
h
e
B
ritish
Jo
u
rn
a
l
o
f
R
a
d
io
lo
g
y,
N
o
ve
m
b
e
r
2
0
1
1
9
7
5
(SS) plans in 25 patients with oropharyngeal or hypo-
pharyngeal cancer found similar PTV coverage with
slightly better conformity in the elective nodal volume
with VMAT. It is worth noting that in this study the
IMRT plans used five or seven fields compared with the
other studies which used seven or nine beams and as
discussed previously, the quality of IMRT plan improves
with increasing number of beams, but at the expense of a
greater number of MU and longer treatment times.
The degree of OAR sparing in the majority of these
planning studies are either not significantly different or
slightly better in the VMAT plans compared with fixed
field IMRT [91, 92] (this excludes the paranasal sinus
group in Guckenberger’s study [94]). Some studies have
also reported lower integral doses to the body with
VMAT plans [92]. However, the volume of area receiving
the lower radiation dose range is greater in VMAT plans.
For instance in the Bertelsen et al study [95], the volume
of the contralateral parotid glands receiving doses less
than 23 Gy was greater in the VMAT plans, but this was
the contrary for doses higher than 23 Gy. This was also
the case for the ipsilateral parotid glands where the
intersection was at approximately 11 Gy. There is a
correlation between the incidence of xerostomia and
mean doses to the parotid glands; it is generally accepted
that mean dose thresholds are used as constraints in the
optimisation process [97, 98]. It remains unclear what the
clinical significance is of the greater volume of glands
receiving low dose radiation. There are preclinical data
suggesting that radiation tolerances of some OARs
(parotid glands and spinal cord) may be reduced when
the OAR regions receiving higher doses are surrounded
by areas receiving lower doses (‘‘the bath and shower’’
effect) [99]. Longer term follow-up will be required to
assess the impact of this on late toxicity.
There is limited data on the comparison between HT
and VMAT in head and neck cancer. Clemente et al [100]
performed a planning study in eight patients with
oropharyngeal tumours comparing a nine-field fixed
field IMRT (SS), double arc VMAT and HT plan. There
was no significant difference in PTV coverage for the
high and intermediate dose levels, but the HT plans were
better than VMAT and IMRT in the coverage of the
elective PTV (D98% was 97.1% in HT plans compared
with 94.5% with IMRT and 92.6% with VMAT). HT was
superior to VMAT and IMRT in terms of dose conformity
and homogeneity while VMAT plans were superior to
IMRT in dose conformity. Dose to brain, parotid, oral
mucosa and oesophagus were all lowest in the HT plans
while VMAT and IMRT plans achieved lower doses to
the mandible. The authors also point out that although
there was better sparing of the OARs outside the PTV,
the doses to OARs embedded in the PTV were higher in
the HT plans compared with VMAT. Another planning
study by Rao et al [61] compared IMRT, VMAT and HT
showed no significant difference in PTV coverage, but
similarly showed lowest mean doses to OARs in the HT
plans. Overall it is felt that HT and VMAT can produce
comparable dose distributions although HT may be
slightly better at treating more complex volumes, for
example if there are multiple targets within a larger
irradiated volume [61].
As in the prostate VMAT planning studies, a universal
finding in these studies was the reduction in MU (up to
46%) with VMAT plans compared with fixed field IMRT
[91–93]. Many of the above studies used seven to nine
fields in their fixed field IMRT plans which used a larger
number of MUs compared with the five-field plans [91,
92, 95]. It is worth bearing in mind again, the number of
MU in fixed field IMRT depends on the IMRT technique;
usually more MU are required in the SW or dynamic
IMRT technique [19, 20]. The differences in MU be-
tween IMRT and VMAT found in studies using step and
shoot IMRT are smaller than in the studies using the SW
technique. Another reported benefit of VMAT is the
shorter delivery time [92, 96]. However, this is dependent
on the number of fields used in the IMRT plans with
seven- or nine-field plans taking slightly longer to deliver
compared with five-field plans [94, 100]. Clemente et al
[100] also commented that in more complex cases, VMAT
delivery time was prolonged and resulted in longer treat-
ment times compared with HT. Preliminary data suggests
that acute toxicity with VMAT in head and neck cancer is
acceptable. Scorsetti et al [101] reported 45 patients who
were treated with VMAT (RapidArc, Varian), of which
78% also received concomitant chemotherapy. In their
patient series, the incidence of NCI CTCAE v.3.0 Grade 3
mucositis was 28%, Grade 3 dermatitis was 14% and
Grade 2 dysphagia was 44%. Late toxicity and clinical
outcome data are awaited.
Dose escalation strategies in head and neck cancer
have been evaluated using fixed field IMRT. The
rationale behind this is the high locoregional relapse
rate despite improvements in therapy and the observa-
tion that the majority of these treatment failures are
occurring within the high dose radiotherapy volume
[102–104]. These regions are thought to represent areas of
hypoxia and radioresistance within the tumour volume
and may require higher doses to improve local control.
The feasibility of dose escalation using fixed field IMRT
has been tested in Phase I studies with acceptable toxicity
rates [105, 106]. Larger randomised trials evaluating this
strategy are now in progress or in set-up. The concept of
dose painting using biological imaging, such as positron
emission tomography (PET) to guide the delineation of
these boost regions has also been of significant interest in
recent years. Fluorine-18-fluorodeoxyglucose (18F-FDG)
has been proposed as a potential tracer to be used in this
way due to its wide availability and correlation with
many biological processes that are associated with
radioresistance including hypoxia, increased cell prolif-
eration and accelerated repopulation. A Phase I trial of 41
head and neck cancer patients has demonstrated the
feasibility and safety of this approach using fixed field
IMRT to boost 18F-FDG avid regions within the gross
target volume (GTV) [107]. At present, one study has
reported on the feasibility of dose painting using VMAT.
Korreman et al [108] tested voxel-based dose painting
in a head and neck cancer patient using 61Cu-diacetyl-
bis (N4-methylthiosemicarbazone) (61Cu-ATSM) PET to
guide delineation of boost volumes and reported this to
be feasible. Further studies are required to evaluate the
potential benefits of this strategy.
A summary of the comparative planning studies
evaluating VMAT in head and neck cancer is presented
in Table 3. An example of the dose distributions
achieved with VMAT and fixed field IMRT for head
and neck cancer is illustrated in Figure 2.
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Table 3. Comparative planning studies in head and neck cancer
Paper [ref]
VMAT
commercial
system
Number of
patients
Primary tumour site Comparison PTV OAR MU per fraction Treatment time per
fraction
Verbakel
et al [91]
RapidArc
12 Nasopharynx,
oropharynx and
hypopharynx
IMRT (7F,SW) vs
VMAT (SA) vs
VMAT (DA)
Similar PTV coverage. DA
VMAT better than SA
VMAT and IMRT for
homogeneity
No significant difference.
Parotid dose lower with DA
VMAT (by average 2Gy)
compared with SA VMAT
and IMRT
VMAT (SA), 439;
VMAT (DA),
459; IMRT,
1108
Vanetti
et al [92]
RapidArc
29 Oropharynx,
hypopharynx
and larynx
IMRT (729F,SW)
vs VMAT (SA)
vs VMAT (DA)
Similar PTV coverage and
conformity. DA VMAT
better than SA VMAT and
IMRT for homogeneity
(SA VMAT slightly inferior
to IMRT)
VMAT better than IMRT at
sparing spinal cord (D2%,
mean dose), brainstem (D2%,
mean dose) and parotid
glands (mean dose). DA
VMAT better than SA VMAT.
VMAT – lower integral doses
to body
VMAT (SA), 463;
VMAT (DA), 584;
IMRT, 1126
VMAT (SA),
1.221.5 min;
VMAT (DA),
3 min;
IMRT, 15 min
Johnston
et al [93]
RapidArc
10 Nasopharynx and
oropharynx
IMRT (9F,SW) vs
VMAT (DA)
Similar PTV coverage IMRT
slightly better than VMAT
for conformity and
homogeneity
No significant differences for
spinal cord, brainstem doses.
VMAT better than IMRT for
contralateral parotid gland
sparing
VMAT, 529;
IMRT, 1628
Guckenberger
et al [94]
SmartArc
15 (of 20) Post-operative
pharynx/ larynx,
primary pharynx,
paranasal sinus
IMRT (9F,SS)
vs VMAT
(123 arcs)
For PTV coverage and
homogeneity: (post-operative
pharynx/larynx) SA VMAT
inferior to IMRT, DA VMAT
5 IMRT TA VMAT better than
IMRT; (primary pharynx) SA and
DA VMAT inferior to IMRT TA
VMAT5 IMRT; (paranasal sinus)
All VMAT plans inferior to IMRT;
(decreased coverage between
orbits)
(Post-operative pharynx/larynx,
primary pharynx) No
significant difference (SA
VMAT inferior to DA VMAT;
TA VMAT and IMRT)
(paranasal sinus) All VMAT
plans inferior to IMRT for
lens sparing
IMRT, 4302688;
VMAT (SA),
3582440;
VMAT
(DA), 460–519;
VMAT (TA),
5062560
IMRT, 9.55212.25
min; VMAT (SA),
1.8522 min;
VMAT (DA),
3.8323.98
min; VMAT (TA),
4.4224.58 min
Bertelsen
et al [95]
Smartarc
25 Oropharynx and
hypopharynx
IMRT (527F,SS)
vs VMAT (SA)
Similar PTV coverage and
homogeneity. VMAT better
than IMRT for elective
PTV coverage and
conformity
VMAT better than IMRT at
sparing spinal cord, parotid
glands, submandibular glands
at high dose levels. VMAT 2
lower volumes of normal
tissue (outside PTV)
irradiated to higher doses
VMAT, 460;
IMRT, 503
VMAT, 4.02 min;
IMRT, 6.2 min
Alvarez-Moret
[96]
Oncentra
Masterplan
4 Oral cavity,
hypopharynx,
nasal cavity
IMRT (729F,SS)
vs VMAT (SA)
vs VMAT (DA)
IMRT and DA VMAT similar
PTV coverage, homogeneity
(SA VMAT inferior to IMRT
and DA VMAT)
IMRT and DA VMAT largely
similar OAR sparing (SA
VMAT inferior to IMRT and
DA VMAT)
VMAT (SA),
491.3; VMAT
(DA), 596.4;
IMRT, 575.4
VMAT (SA),
1.86 min;
VMAT (DA),
3.64 min; IMRT,
11.7 min
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Thoracic tumours
The use of IMRT has been evaluated in the treatment
of lung cancer and has been shown to improve dose
conformity and OAR sparing [109, 110]. The impact of
intrafraction motion in these cases can be significant and
can potentially reduce target volume coverage or cause a
geographical miss and increase doses to OARs. Various
approaches to manage intrafraction motion include using
four-dimensional (4D)-CT scanning that allow visual-
isation of all the possible tumour positions within the
respiratory cycle, which can then be incorporated with a
safety margin in the PTV, breath-hold techniques (e.g.
active breathing control), delivery gating and marker
tracking [111–113]. The issue of treatment delivery time
per fraction is also important as the degree of intrafraction
motion has been found to increase with time [114]. VMAT
would be an attractive solution because IMRT quality
dose distributions can still be achieved, but in a shorter
treatment time that could minimise the effect of intrafrac-
tion motion. Although motion-adaptive radiotherapy is
currentlywidely usedwith conventional fixed field IMRT,
it has not yet been routinely implemented with VMAT.
The feasibility of tracking target motion for arc therapy
using a dynamic MLC algorithm has been evaluated in a
recent study and has shown encouraging results, but
further research in this area is warranted [115].
Lung cancer
For early stage lung cancers e.g. Stage I non-small cell
lung cancer (NSCLC), stereotactic body radiotherapy
(SBRT) has emerged as an alternative treatment option to
surgical resection for patients who are medically inoper-
able, giving excellent local control rates (up to 95%) [116,
117]. SBRT is usually delivered with hypofractionated
radiotherapy schedules and using multiple non-coplanar
fixed beams occasionally combined with dynamic arcs.
IMRT and HT have also been evaluated using this
approach. These techniques can improve dose conformity
compared with conventional radiotherapy, but at the
expense of prolonged delivery time [118, 119]. Several
planning studies have evaluated the performance of
VMAT in delivering SBRT for lung cancer. Mcgrath et al
[120] compared VMAT to conventional 3D-CRT (using 7–
10 non-coplanar beams) in 21 patient datasets with Stage
Ia NSCLC. VMAT was planned using a single 180u partial
arc with the arc range selected to avoid as much of the
contralateral lung as possible. The dose prescription to the
PTV/internal target volume was 48 Gy in 12 fractions.
The results report improved conformity with VMAT at
the 80% and 50% isodose levels, although there was no
significant difference at the 95% isodose level. VMAT
achieved improved sparing of the lung parenchyma with
significantly lower doses to the volume receiving 20 Gy,
12.5 Gy, 10 Gy and 5 Gy.
The improved dose conformity at the 80% and 60%
isodose levels was also seen in the study by Ong et al
[121], which evaluated 18 patients with Stage I NSCLC
comparing double arc VMAT with conventional 3D-
CRT, dynamic conformal arcs and IMRT (SW). However,
they report higher doses to the ipsilateral and contral-
ateral lungs in the VMAT plans compared with thePa
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conventional CRT plans. A possible reason for this is that
partial arcs avoiding the contralateral lung were not used
in this study. In addition, the authors also specify that
the plans were optimised taking into consideration dose
constraints to the chest wall because there is evidence
that lower V30 Gy for the chest wall is associated with
lower risk of late toxicity e.g. rib fractures. As a result, the
doses to the chest wall in this study were significantly
lower in the VMAT plans, but at the cost of increased
dose to the lungs. A recent study conducted by a Dutch
group compared coplanar VMAT with non-coplanar and
coplanar IMRT in 27 patient datasets [122]. The VMAT
plans used double partial arcs avoiding the contralat-
eral lung. While PTV coverage was similar between all
three techniques, both non-coplanar IMRT and coplanar
VMAT performed better then coplanar IMRT in reducing
dose to healthy lung tissue. Non-coplanar IMRT had
slightly better conformity and lower V20 Gy for normal
lung compared with coplanar VMAT. Another recent
study by Brock et al [123] reported improved target
volume coverage with VMAT and non-coplanar CRT
techniques compared with coplanar techniques. VMAT
resulted in slightly higher lung V11 Gy but lower
V20 Gy compared with the non-coplanar plans (not
statistically significant).
All these studies report improved treatment efficiency
with reduction in treatment delivery time. Mcgrath et al
[120] reported a reduction in delivery time with VMAT
of 37–63%. In the Ong et al study [121], three fractiona-
tion schedules (54 Gy in 3 fractions, 55 Gy in 5 fractions
or 60 Gy in 8 fractions) were evaluated based on a risk-
adapted fractionation scheme that is dependent on factors
including tumour size and position. Unsurprisingly the
delivery times for the schedules with larger dose per
fractions were longer (10.3 min for 54 Gy in 3 fractions
and 3.9 min for 60 Gy in 8 fractions). This was compared
with an average delivery time of 12 min with IMRT and
11.6 min with conventional 3D-CRT, which did not vary
significantly between the different fractionation sche-
dules. In Ong et al’s study [121], MU with VMAT were
higher than conventional CRT but significantly lower
compared with IMRT (average MU/Gy was 240 with
VMAT with 445 with IMRT). However, this was not seen
in the study by Holt et al [122] where the number of MUs
used in the VMAT and IMRT plans were not significantly
different.
There is limited data on the comparison of HT and
VMAT in lung cancer. In the study by Rao et al [61]
comparing VMAT with HT and fixed field IMRT (SS),
6 cases of lung cancer (out of a total of 18 patient datasets)
(a) (b)
(c) (d)
Figure 2. Example of dose distributions in (a,b) IMRT and (c,d) VMAT plans for oropharyngeal cancer. The dose prescribed to
the primary planning target volume (PTV) (encompasses the tumour and involved lymph nodes) and elective PTV (regional
lymph nodes at risk of microscopic spread) is 65 Gy and 54 Gy in 30 fractions, respectively. The primary PTV (red contour) is
encompassed by the 95% isodose (orange line and colour wash) and the elective PTV (pink contour) is encompassed by the
78.9% isodose (dark blue line and light green colour wash). Some sparing of the parotid gland (light blue contour) is achieved.
Figures courtesy of Department of Medical Physics, Royal Surrey County Hospital, UK.
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were evaluated. All three plans resulted in largely similar
PTV coverage and OAR sparing. Lung mean doses and
V20 Gy were slightly lower in the IMRT plans compared
with HT and VMAT, but this was not statistically sig-
nificant. The main benefit seen with VMAT is the reduc-
tion in treatment delivery time (average of 2.1 min per
fraction compared with 5.4 and 7.9 min for HT and IMRT,
respectively).
Limited data is available for the use of VMAT in more
advanced lung tumours. One early paper presented a
case study of small cell lung cancer that was treated with
VMAT and reported slightly improved PTV coverage
and a slightly reduced lung V20 Gy compared with
conventional CRT techniques [124]. Scorsetti et al [125]
evaluated planning and clinical outcomes in 24 patients
with locally advanced NSCLC (Stage IIIA2IIIB) treated
with VMAT (RapidArc, Varian) at their unit. They report
satisfactory target coverage and homogeneity with doses
to OARs within acceptable tolerances. Acute toxicity was
also acceptable with no Grade 3 toxicities reported.
Target volumes in these advanced cases are often large,
which results in a large volume of normal lung receiving
low dose radiation (V5 Gy) with any IMRT technique
including fixed field IMRT and VMAT.
The increase in normal tissue volume receiving low
dose radiation seen in VMAT has raised some concern.
In addition to the potential increased risk of secondary
malignancy induction, there have been anecdotal obser-
vations that the rate of radiological pneumonitis may be
higher in patients treated with VMAT compared with
conventional 3D-CRT (this is in SBRT follow-up). Palma
et al [126] conducted a matched analysis of patients who
had received SBRT with VMAT or conventional 3D-CRT
to evaluate the patterns of radiological changes and severity
of pneumonitis. They report no statistically significant
differences in either endpoint, although 12% of patients
receiving VMAT had what was classified as severe radio-
logical changes comparedwith 2% of conventional 3D-CRT
patients. However, despite over 50% of patients showing
acute radiological changes, only 5% of patients had the
clinical symptoms of pneumonitis. It is worth noting that in
their practice, patients are treated with at least two full arcs
with or without the addition of partial arcs, as opposed to
exclusive partial arcs with avoidance of the contralateral
lung. In addition, these patients were assessed and imaged
at 3 months post-treatment in this study, which may be too
early to evaluate the rates of late onset pneumonitis and
fibrosis.
Mesothelioma
In terms of other thoracic histological tumour types,
IMRT techniques have been evaluated in the treatment of
malignant pleural mesothelioma (MPM). Post-operative
radiotherapy following chemotherapy and surgery (extra-
pleural pneumonectomy) has been used to try to improve
locoregional control and survival in this disease, which is
associated with a poor prognosis [127]. Conventional
techniques provide suboptimal dose coverage owing to
the complexity of the target volume, which is often large,
irregular in shape and in close proximity to numerous
critical structures (lung, liver, spinal cord, heart, oesopha-
gus and kidneys). Double arc VMAT was evaluated in a
recent planning study of six patients with MPM and
compared with nine-field fixed field IMRT (SW) [128].
PTV coverage, dose homogeneity and conformity were
largely equivalent between the two techniques. In terms of
OAR sparing, VMAT plans achieved significantly lower
mean doses to the contralateral kidney, heart, liver and
oesophagus, and lower V20 Gy for the contralateral lung.
The reduction in MU (average MU per 2 Gy was 734 vs
2195) and treatment delivery time (3.7 min vs 13.4 min)
was a further benefit of VMAT found in this study.
A summary of the comparative planning studies
evaluating VMAT in thoracic tumours is presented in
Table 4.
Central nervous system tumours
Benign lesions
Radiotherapy for intracranial tumours can be chal-
lenging owing to the proximity of these tumours to
numerous critical structures. In particular, the use of
radiation in the management of benign intracranial tu-
mours where long life expectancies are predicted raises
the need for highly conformal techniques to reduce
radiation dose to the surrounding normal tissue. IMRT,
Cyberknife, HT and stereotactic techniques have all been
evaluated in this clinical setting. Fogliata et al [129]
evaluated VMAT in comparison with 5–7 field fixed field
IMRT (SW) andHT in a planning study of 12 patients with
benign intracranial tumours. These included five acoustic
neuromas, five meningiomas and two pituitary adeno-
mas. The results showed equivalent PTV coverage with
arc therapies performing slightly better than IMRT.
VMAT and IMRT plans were superior in OAR sparing
and reducing integral dose compared with HT. IMRT
performed slightly better than VMAT plans in reducing
doses to OARs, healthy brain and healthy tissue especially
at low dose levels (below 10 Gy). This may be significant
in this patient cohort where the risk of radiation-induced
secondary malignancy should be minimised as much as
possible.
Another study by Lagerwaard et al [130] compared
single arc VMAT with their standard technique used for
frameless radiosurgery of five non-coplanar dynamic
conformal arcs (5DCA) and a third plan of single dynamic
conformal arc (1DCA). In the three patient datasets with
varying sizes of acoustic neuroma (small, 0.5 cm3; inter-
mediate, 2.8 cm3 and large, 14.8 cm3), PTV coverage was
similar between the three plans with VMAT plans showing
improved conformity comparedwith the 5DCA and 1DCA
plans. Maximum doses to OARs were lower in the VMAT
and 5DCA plans comparedwith the 1DCA plans and there
was a reduction in the volume of normal brain receiving
low dose radiation (below 1 Gy) with VMAT and 1DCA
compared with 5DCA plans. No significant difference
was found in the number of MU between VMAT and
5DCA plans, but treatment time was reduced. This is
important as the risk of inaccuracies due to intrafraction
motion can be reduced. The authors also postulate that the
quality of VMAT plans may possibly be further improved
if the high definitionMLCs (2.5 mmwidth comparedwith
standard 5 mmwidth) were used. Both these studies used
coplanar fields for the VMAT plans and the authors
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Table 4. Comparative planning studies in thoracic tumours
Paper [ref] VMAT
commercial
system
Number of
patients
Stage and dose Comparison PTV OAR MU per fraction Treatment time per
fraction
McGrath
et al [120]
21 Stage Ia NSCLC
SBRT 48 Gy in
12 fractions
3D-CRT (7210
non-coplanar) vs
VMAT (single
partial arc)
VMAT better than 3D-CRT for
conformity at 80% and 50%
isodose levels. No difference
in homogeneity
VMAT better than 3D-CRT at
sparing lung (V20 Gy,
V12.5 Gy, V10 Gy, V5 Gy). No
significant difference in
mean dose to other OARs
VMAT, 2360;
3D-CRT, 2235
VMAT reduced
treatment time
by 37263%
compared with
3D-CRT
Ong
et al [121]
Rapidarc
18 Stage I NSCLC
SBRT 54Gy in 3
fractions 55Gy
in 5 fractions
60Gy in 8
fractions
3D-CRT non-coplanar
(10F) vs DCA vs IMRT
(9210F coplanar),
SW vs VMAT (DA)
VMAT better than 3D-CRT,
DCA and IMRT for
conformity at 80% and
60% isodose levels
VMAT – higher lung doses
(V20Gy,V5Gy) compared with
3D-CRT (no significant
difference with IMRT). VMAT 2
better sparing of chest wall
(V45Gy, V30Gy, V20Gy)
compared to 3D-CRT, DCA
and IMRT
VMAT,
180024320;
3D-CRT,
134323222;
DCA,
140223364;
IMRT,
333828010
VMAT,
3.9210.5 min;
3D-CRT, 11.6 min;
IMRT, 12 min
Holt
et al [122]
SmartArc
27 Stage I/IIa NSCLC
SBRT 54Gy in
3 fractions
Coplanar IMRT (9F)
vs non-coplanar
IMRT (12216F) vs
VMAT (DA)
Similar PTV coverage VMAT
better than coplanar IMRT
but inferior to non-coplanar
IMRT for conformity at 50%
isodose level. Non-coplanar
IMRT better than coplanar
IMRT for conformity at 75%
and 50% isodose levels
VMAT inferior to non-coplanar
IMRT for lung V20Gy, spinal
cord (Dmax), oesophagus
(Dmax) and chest wall V30Gy.
VMAT and non-coplanar
IMRT better than coplanar IMRT
for lung V20Gy, spinal cord and
oesophageal Dmax
VMAT, 3428;
coplanar
IMRT, 3335;
non-coplanar
IMRT, 3313
VMAT, 6.5 min;
Coplanar IMRT,
17 min;
non-coplanar
IMRT, 23.7 min
Brock
et al [123]
5 Stage I NSCLC
SBRT 60Gy in
8 fractions
Coplanar and
non-coplanar CRT
(3F, 5F, 7F, 9F)
vs VMAT
Non-coplanar and VMAT
better than co-planar
for PTV coverage
Non-coplanar CRT better than
coplanar CRT for lung V11Gy
(no significant difference for
V20Gy). VMAT slightly higher
V11Gy and lower V20Gy
compared with non-coplanar
CRT (not statistically significant)
VMAT, 2.13 min;
non-coplanar (5F),
12.67 min;
(7F), 7.75 min
Rao
et al [61]
SmartArc
6 (of 18) Not specified IMRT (7F,SS) vs
VMAT (SA) vs HT
Similar PTV coverage,
homogeneity
IMRT – slightly lower lung mean
dose and V20Gy (not statistically
significant)
VMAT, 476;
IMRT, 569
VMAT, 2.1 min;
IMRT, 7.9 min;
HT, 5.4 min
Scorsetti [128]
RapidArc
6 Mesothelioma IMRT (9F,SW) vs
VMAT (DA)
Similar PTV coverage VMAT better than IMRT at sparing
some OAR (contralateral lung
V20Gy, kidney D1%, heart
mean dose, liver mean dose)
VMAT, 734;
IMRT, 2195
VMAT, 3.7 min;
IMRT, 13.4 min
VMAT, volumetric modulated arc therapy; PTV, planning target volume; OAR, organs at risk; MU, monitor units; NSCLC, non small cell lung cancer; SBRT, stereotactic body
radiotherapy; Gy, Gray; 3D-CRT, three-dimensional conformal radiotherapy; V20Gy, volume receiving >20Gy; V12.5Gy, volume receiving >12.5Gy; V10Gy, volume receiving
>10Gy, V5Gy, volume receiving >5Gy; DCA, dynamic conformal arcs; IMRT, intensity modulated radiotherapy; V45Gy, volume receiving >45Gy; V30Gy, volume receiving
>30Gy;3F, three field; 5F, five field; 7F, seven field; 9F, nine field; 12F, twelve field, 16F, sixteen field; SW, sliding window; SS, step-and-shoot; SA, single arc; DA, double arc; Dmax,
maximum dose; V11Gy, volume receiving >11Gy; HT, helical tomotherapy; D1%, dose to 1% of volume.
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discuss the possibility of improving the quality of these
plans by using non-coplanar and/or multiple arcs.
Malignant glioma
For malignant gliomas, IMRT has been evaluated with
several planning studies showing a dosimetric super-
iority for non-coplanar IMRT techniques compared with
conventional 3D-CRT [131]. Malignant gliomas are widely
infiltrative in their extension with indistinct tumour
margins that are difficult to accurately define. There is
therefore a concern of increased risk of insufficient dosage
of the target volume, especially with the steep dose
gradients in IMRT plans. However, with more sophisti-
cated imaging modalities to guide definition of tumour
margins, the ability to co-register diagnostic MRI with
planning CT images for improved accuracy of target
volume delineation as well as the potential benefit of
improved OAR sparing and facilitation of dose escalation,
IMRT should be considered as a potentially useful tech-
nique for the treatment of these often aggressive tumours.
Wagner et al [132] conducted a planning study of 14
patients with malignant glioma (World Health Organiza-
tion (WHO) Grade 3 or 4) comparing single arc VMAT
with 5–9 field fixed field IMRT (SW) and 3D-CRT.
Conformity was higher for VMAT and IMRT compared
with 3D-CRT; VMAT performed slightly better than IMRT
in this respect. However, PTV coverage (which in this
study was calculated as the ratio of target volume covered
by the 95% isodose line divided by the PTV volume) was
superior in IMRT compared with VMAT (94.7% vs 90.5%).
For PTVs that were distant to OARs, 3D-CRT performed
as well as IMRT in terms of PTV coverage, but was
significantly inferior to both IMRT and VMAT for PTVs
that were situated close to OARs. Regarding OAR sparing,
VMAT achieved slightly better sparing compared with
the other two techniques. The volume of healthy tissue
receiving low dose radiation (V5 Gy) and mean dose of
healthy brain was the highest in VMAT plans and lowest
in 3D-CRT plans (mean dose 27.9 Gy vs 25.8 Gy).
Another study by Shaffer et al [133] evaluated VMAT
in 10 patients with WHO Grade 3 or 4 glioma and
compared the VMAT plans with 7-field fixed field IMRT
(SW). The authors attempted to reduce bias in their study
by cross-planning between two experienced planners,
each generating five new IMRT and VMAT plans to
avoid systematic planner bias. The patient datasets were
also selected to include only cases where the PTV over-
lapped with at least one OAR therefore increasing the
difficulty and complexity of planning. The results essen-
tially showed equivalence in PTV coverage, conformity
and homogeneity between the two techniques. For OAR
sparing, VMAT and IMRT achieved similar sparing of
midline OARs (brainstem and optic chiasm), but VMAT
was better at sparing peripheral OARs with a lower mean
dose to the retina, optic nerve and lens. Similar to Wagner
et al’s study [132], the mean dose to normal brain
was significantly higher in the VMAT plans (by 12%)
compared with IMRT.
While it is difficult to make definite conclusions from
these planning studies, owing to their limitations, some
recommendations have been discussed. Wagner et al
[132] suggest, for PTVs situated distant to OARs, 3D-CRT
can achieve comparable and acceptable PTV coverage
with better sparing of healthy brain and normal tissue
and therefore would be the technique of choice. How-
ever, for PTVs close to OARs, either IMRT or VMAT
would be preferable depending on the adequacy of PTV
coverage, while bearing in mind the added benefit of
reduced MU and treatment time with VMAT. Therefore,
the preferred radiation technique for these tumours
should be selected on an individual case basis and in
certain situations IMRT or VMATmay not always offer the
optimal solution. Regarding the issue of increased radia-
tion to healthy brain tissue, Shaffer et al [133] postulate that
this could possibly be reduced by setting constraints for
normal brain in the optimisation process or using multi-
ple, partial and/or non-coplanar arcs to avoid entry and
exit beams through critical normal tissue structures.
Metastatic lesions
In the palliative setting, randomised data has shown
improvements in survival with the combination of
radiosurgery and whole brain radiotherapy (WBRT)
compared with WBRT alone for brain metastases [134].
Stereotactic radiosurgery can either be delivered using
linear accelerator-based treatment with multiple static or
conformal arcs, or using gamma knife radiosurgery with
multiple highly collimated cobalt sources. Historically,
this strategy has been reserved for patients with solitary
metastasis or oligometastatic diseases (#3 lesions). How-
ever, several studies have recently evaluated the feasi-
bility of using VMAT to deliver either a single fraction
radiosurgical boost or fractionated ‘‘stereotactic’’ boost
to multiple brain metastases. Lagerwaard et al [135]
compared WBRT with SIB to the metastatic lesions using
double arc VMAT, with their conventional strategy of
WBRT followed sequentially by a single stereotactic boost
(21 Gy to 80% isodose) using multiple non-coplanar
conformal arcs. For the integrated VMAT plan, the total
dose to the metastatic lesions was 40 Gy in 5 fractions
(WBRT dose prescription was 20 Gy in 5 fractions). They
found satisfactory coverage for the boost and WBRT PTV
in the integrated plans and much steeper dose gradients
outside the boost PTV, which resulted in improved con-
formity compared with the conventional strategy. The
volume of normal brain receiving between 25 Gy and
35 Gy was lower in the integrated VMAT plans but the
maximum dose to the lenses was higher compared with
the conventional technique (9.5 Gy vs 5 Gy). Ma et al [136]
conducted a planning study evaluating hypofractionated
stereotactic radiotherapy (dose prescription of 50 Gy in 10
fractions) in 10 patients with between 2 and 4 brain
metastases. Single and double arc VMAT plans were
compared with seven-field fixed field IMRT (SS). PTV
coverage was similar between VMAT and IMRT with
slightly better conformity and homogeneity in the double
arc VMAT plans. Double arc VMAT plans also resulted in
slightly lower maximum doses to the brainstem and optic
structures compared with fixed field IMRT. However, the
percentage of healthy tissue volume receiving 5 Gy was
larger with VMAT (56.7% single arc, 57.1% double arc)
compared with fixed field IMRT (52.9%).
In another study by Clark et al [137], three VMAT
plans were generated for four simulated cases that
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varied with regard to spacing between the lesions (either
3 cm or 6 cm apart) and axial planes (either same or
different planes). The VMAT plans included a single arc/
single isocentre (SASI), triple arc/single isocentre (TASI)
and triple arc/triple isocentre (TATI) plan. Conformity
was better in themulti-arc plans; the TASI plan performed
better than the TATI plan. This was also the case with the
size of the 12 Gy isodose volumes, which is considered
an important predictor of normal tissue complications
including radiation necrosis. These differences were more
pronounced in the cases where lesions were situated in
close proximity, leading the authors to conclude that for
less demanding cases, where lesions are spaced widely
apart, a single arc technique can produce adequate plans.
For more complex cases, multi-arc techniques are superior
to single arc with no significant differences between single
or triple isocentre techniques. Single isocentre techniques
would be preferable as treatment time is shorter and there
is less potential for set-up error. Another feasibility study
by Hsu et al [138] found that VMAT was able to deliver
WBRT with SIB for 1–3 brain metastases with the addition
of hippocampal avoidance, which could potentially
reduce the risk of neurocognitive dysfunction.
Spinal metastatic disease is another palliative setting
where IMRT techniques could play a role. This common
complication of many malignant tumours can lead to sig-
nificant morbidity in terms of severe pain and neurolo-
gical dysfunction including paralysis in the case of
spinal cord compression. The radiation dose that can be
delivered using conventional radiotherapy techniques
are limited by dose constraints set to minimise spinal
cord toxicity. This limitation may be overcome by the use
of SBRT using highly conformal intensity modulated
radiation techniques. Two separate planning studies by
Kuijper et al [140] and Wu et al [139] compared VMAT
with fixed field IMRT to deliver SBRT to vertebral
metastases. In Wu et al’s study [139], IMRT plans (SW)
using 8–12 static beams were compared with single and
double arc VMAT. PTV coverage was comparable, but
conformity was best with double arc VMAT. IMRT was
best at spinal cord sparing while double arc VMAT was
better than single arc in this respect. In Kuijper et al’s
study [140], fewer beams were used in the IMRT plans
(7–9 fields, SW) and they evaluated two or three arcs in
the VMAT plans. Their results showed equivalence in
terms of PTV coverage and OAR sparing, although con-
formity was better with VMAT. This study did not show
any reduction in MU and treatment time, which is
contrary to Wu et al’s [139] findings. This could be
explained by the greater number of beams in the IMRT
and fewer arcs in the VMAT plans in Wu et al’s study
[139]. A further finding from Kuijper et al’s study [140] is
that although IMRT and VMAT can achieve adequate
PTV coverage in cases where only the vertebral body was
treated, the PTV coverage is compromised with both
techniques where the target volume was more complex
and included the entire vertebra (vertebral body, pedicles
and posterior elements). Furthermore, while these results
are encouraging, these advanced radiotherapy techniques
require lengthy planning and QA procedures and may be
unrealistic for case scenarios such as spinal cord compres-
sion where urgent initiation of treatment is of paramount
importance. As a result, most of these patients will still
receive standard conventional radiotherapy. A proportion
of these patients (25–40%) may develop troublesome in-
field local recurrences following their initial treatment.
The feasibility of reirradiation with conventional, and
more recently IMRT techniques, has been studied. Mancosu
et al [141] evaluated VMAT in this setting and found that
this technique could achieve satisfactory PTV coverage
and spinal cord sparing. Further trials to evaluate clinical
outcomes (local control and symptom palliation) with this
strategy are in progress.
A summary of the comparative planning studies
evaluating VMAT in central nervous system tumours is
presented in Table 5. An example of dose distributions
achieved with VMAT and fixed field IMRT for malignant
glioma is illustrated in Figure 3.
Breast cancer
VMAT has been investigated in a number of different
scenarios. Qiu et al [142] conducted a planning study for
partial breast radiotherapy in eight patients comparing
conventional CRT using four to five non-coplanar fields
with VMAT using a modified partial arc. The results
showed similar target volume coverage; VMAT had
slightly better conformity, although this was not statisti-
cally significant. The doses to the ipsilateral lung and
ipsilateral normal breast tissue were significantly reduced
with VMAT. V20 Gy for the ipsilateral lung was 0.5% in
VMAT plans compared with 1.6% in CRT plans while
V5 Gy for the ipsilateral breast was 59.6% and 70% for the
VMAT and CRT plans, respectively. VMAT also used
fewer MU and reduced treatment time compared with
conventional radiotherapy. Although partial breast radio-
therapy is increasingly considered acceptable for selected
patients, this strategy is still not widely used outside of
clinical trials and longer follow-up of these patients is
needed to assess the long term clinical outcomes. Radio-
therapy to the whole breast and/or regional lymph nodes
remains the gold standard.
The irradiation of internalmammary lymph nodes is not
considered standard practice in the UK, but it is performed
for selected patients with high risk breast cancer at several
institutions worldwide. Conventionally this is done using
the modified wide tangent (MWT) technique, which in-
creases the volume of normal tissue (particularly lung and
heart) receiving radiation. Popescu et al [143] evaluated
VMAT against the conventionalMWT technique and nine-
field fixed field IMRT (SW) in a group of patients with left-
sided breast cancer who also received radiotherapy to the
internal mammary nodes. They report similar PTV cover-
age, dose homogeneity and conformity, but improved
sparing of OARs with VMAT, particularly for the heart,
ipsilateral lung and contralateral breast. Another similar
study by Johansen et al [144] found similar PTV coverage,
but improved conformity with IMRT (SW) and VMAT
compared with conventional techniques and better homo-
geneity with VMAT. In their study, there was improved
sparing of the ipsilateral lung and contralateral breast with
VMAT, but no significant differences in cardiac doses.
However, only 3 out of the 8 were left-sided tumours,
therefore, definite conclusions on cardiac-sparing cannot
be made from this study.
Another potential area where IMRT techniques could
play a useful role is in the treatment of large target
Review article: A review of volumetric modulated arc therapy
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Table 5. Comparative planning studies in central nervous system tumours
Paper [ref] VMAT
commercial
system
Number of
patients
Type + Dose Comparison PTV OAR MU per fraction Treatment time
per fraction
Fogliata
et al [129]
RapidArc
12 Acoustic neuroma,
meningioma,
pituitary
adenoma
Non-coplanar
IMRT
(527F,SW) vs
VMAT vs HT
VMAT and HT slightly better
than IMRT for PTV coverage
(D99%, D98%). VMAT and
IMRT slightly better than HT
for conformity
VMAT and IMRT better than HT
at sparing OARs (brainstem,
optic structures). VMAT and
IMRT – lower integral dose
to body compared with HT
Lagerwaard
et al [130]
RapidArc
3 Acoustic neuroma
(radiosurgery
single 12.5Gy)
VMAT (SA) vs
1DCA vs
5DCA
Similar PTV coverage. VMAT
better than DCA for
conformity
VMAT and 5DCA – similar
maximum doses for cochlea,
brainstem, trigeminal nerve
(1DCA gave higher doses
compared with VMAT and
5DCA). VMAT and 1DCA –
smaller volume of normal
brain receiving low dose
radiation compared with
5DCA
VMAT,
276322869;
5DCA,
248322769
VMAT, 425 min;
5DCA, 20 min
Wagner
et al [132]
RapidArc
14 High grade glioma 3D-CRT (228F)
vs IMRT
(529F,SW) vs
VMAT (SA)
IMRT better than VMAT and
3D-CRT for PTV coverage.
3D-CRT as good as IMRT and
VMAT for coverage of PTVs
distant from OAR but
significantly inferior for PTVs
close to OARs. VMAT slightly
better than IMRT for
conformity (both VMAT
and IMRT better than CRT)
VMAT slightly better than IMRT
and 3D-CRT for OAR sparing
(chiasm, brainstem). VMAT –
highest mean dose to normal
brain and V5Gy of healthy
tissue
VMAT, 321.1;
IMRT, 587.8;
CRT, 224
VMAT 56 faster
than IMRT;
1.26 faster
than CRT
Shaffer
et al [133]
RapidArc
10 High grade glioma IMRT (7F,SW)
vs VMAT (SA)
Similar PTV coverage,
conformity and homogeneity
VMAT better than IMRT at sparing
lateralised OARs (retina, lens,
optic nerves). No significant
differences in sparing of
centralised OARs (brainstem,
chiasm). VMAT – higher mean
dose to normal brain (by 12%)
VMAT, 363;
IMRT, 789
VMAT, 1.8 min;
IMRT; 5.1 min
Lagerwaard
et al [135]
RapidArc
8 Brain metastases
(125)
WBRT + SIB with
VMAT 40Gy in
5 fractions
(integrated
plans) vs
conventional
WBRT +
stereotactic
boost 21Gy
(summated
plans)
Integrated plans (VMAT)
significantly better than
summated plans for
conformity
Integrated plans (VMAT) – smaller
volume of normal brain receiving
25235Gy. Integrated plans
(VMAT) – higher maximum
dose to lenses
Integrated
plans (VMAT),
1600
Integrated plans
(VMAT), 3 min
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Paper [ref] VMAT
commercial
system
Number of
patients
Type + Dose Comparison PTV OAR MU per fraction Treatment time
per fraction
Ma
et al [136]
RapidArc
10 2–4 brain
metastases
IMRT (7F,SS) vs
VMAT (SA) vs
VMAT (DA)
Similar PTV coverage. DA
VMAT slightly better than
SA VMAT and IMRT for
conformity and homogeneity
DA VMAT better than IMRT at
sparing brainstem, optic nerves,
lenses (lower maximum doses).
VMAT – higher V5Gy healthy
tissue, but lower V15Gy and
V20Gy compared with IMRT
IMRT, 1944;
VMAT (SA),
1199; VMAT
(DA), 1387
(Beam on time)
IMRT, 6.5 min;
VMAT (SA),
1.25 min;
VMAT
(DA), 2.5 min
Wu
et al [139]
RapidArc
10 Spinal metastases
SBRT 16Gy single
fraction
IMRT, (8212F,
SW) vs VMAT
(SA) vs VMAT
(DA)
Similar PTV coverage. DA VMAT
better than SA VMAT and
IMRT for conformity
IMRT better than VMAT for
spinal cord sparing
(significant difference for SA
VMAT vs IMRT but not
significant for DA VMAT vs
IMRT)
VMAT (SA),
7730;
VMAT(DA),
6317; IMRT,
8711
VMAT,
7.928.6 min;
IMRT,
15.9 min
Kuijper
et al [140]
RapidArc
5 Spinal metastases
SBRT 16Gy Group
1: PTV5 vertebral
body only Group
2: PTV 5entire
vertebra
IMRT (729F,SW)
vs VMAT
(223 arcs)
Group 1: Similar and acceptable
PTV coverage. VMAT better
than IMRT for conformity;
Group 2: Similar but inadequate
PTV coverage. VMAT better
than IMRT for conformity
Group 1: Similar OAR sparing;
Group 2: VMAT slightly
better than IMRT for spinal
cord sparing
Group 1: VMAT,
7816; IMRT,
5660; Group
2: VMAT,
9019; IMRT,
9399
Group 1: VMAT,
13.5 min; IMRT,
12.5 min;
Group 2:
VMAT,
16 min; IMRT,
19220 min
VMAT, volumetric modulated arc therapy; PTV, planning target volume; OAR, organs at risk; MU, monitor units; IMRT, intensity modulated radiotherapy; 5F, five field; 7F, seven
field; 9F, nine field; 2F, two field; 8F, eight field; 12F, twelve field; SW, sliding window; SS, step-and-shoot; HT; helical tomotherapy; D99%, dose to 99% of volume; D98%, dose to
98% of volume; SA, single arc; DA, double arc; DCA, dynamic conformal arc; 3D-CRT, three-dimensional conformal radiotherapy; V5Gy, volume receiving >5Gy; WBRT, whole
brain radiotherapy; SIB, simultaneous integrated boost; V15Gy, volume receiving >15Gy; V20Gy, volume receiving >20Gy; SBRT, stereotactic body radiotherapy.
Table 5. Continued
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volumes where there is risk of increased radiation dose
to OARs (e.g. in bilateral breast cancer) or complex-
shaped target volumes (e.g. in patients with an unusually
shaped chest wall, such as in cases of pectus excavatum).
Nicolini et al [145] conducted a planning study in 10
patients treated for bilateral breast cancer with an SIB
technique comparing VMAT and fixed field IMRT (SW).
Similar target coverage was found with better dose
homogeneity with VMAT. The doses to the heart were
lower with VMAT while for the lungs VMAT achieved
better sparing at the mid- to high-dose levels (e.g. V20 Gy
right lung 10.3% (VMAT) vs 14.5% (IMRT)) compared
with IMRT, which gave better sparing at low dose levels
(e.g.V5 Gy right lung 58.3% (VMAT) vs 44.4% (IMRT)).
The mean and integral dose to healthy tissue was higher
with VMAT in this study. In Popescu et al’s study [143],
the mean dose to healthy tissue was lower with VMAT,
but V5 Gy for healthy tissue was higher, which is con-
sistent with inferior sparing at low dose levels. Another
important factor in this patient cohort is the effect of
intrafraction motion, which could lead to increased doses
to OARs. Although the shorter treatment time with VMAT
could reduce the impact of motion, other methods to
account for this (e.g. breath-hold or target tracking tech-
niques) should also be considered.
The increase in low dose radiation to healthy tissues
with IMRT techniques is a concern in this patient cohort.
Breast cancer mortality is decreasing owing to a com-
bination of factors including earlier diagnosis via screen-
ing and improvements in therapy. Many patients now
survive for many years after diagnosis and treatment for
breast cancer. It is therefore important to minimise late
side effects that could arise from their treatment. Apart
from cardiovascular disease, secondary malignancy is a
significant cause of non-breast cancer mortality in long-
term survivors [146]. The increased risk of secondary
malignancy secondary to low dose radiation is currently
not accurately quantifiable but should be borne in mind
when deciding on the treatment strategy or radiation
technique for these patients. IMRT will still play an
important role in breast radiotherapy, particularly within
the setting of partial breast dose escalation for high-risk
disease, which is currently being investigated in the
IMPORT-HIGH trial [147]. IMRT techniques can be
refined to minimise the amount of low dose radiation
to healthy tissues e.g. by setting dose constraints on
additional normal tissue structures in the optimisation
process or, in the case of VMAT, using partial arcs. While
inverse planned IMRT is necessary for complex target
volumes, simpler forward planned techniques using
multiple segmented tangential fields may be able to
produce acceptable dose distributions for less complex
cases while also minimising low dose radiation to
surrounding normal tissue. As with other tumour sites,
it may be that there is no universal optimal solution and
the selection of the most appropriate radiation technique,
be it conventional CRT, IMRT or VMAT, must be made
on an individual case basis.
A summary of the comparative planning studies
evaluating VMAT in breast cancer is presented in
Table 6.
Other tumour sites and types
Lymphoma
VMAT for early Hodgkin’s lymphoma was evaluated
in a recent planning study [148]. In this patient cohort the
remission rates following treatment are high, which can
lead to long life expectancies and the need to reduce the
rates of late toxicity, such as secondary cancers and
cardiac morbidity. Weber et al [148] compared single arc
VMAT with nine-field fixed field IMRT (SW) and found
largely equivalent target coverage, homogeneity and
conformity, but improved sparing of lung and breast
tissue in the intermediate dose levels with VMAT
(improvement in V10 Gy and D33%). No significant
(a) (b)
Figure 3. Example of dose distributions in (a) IMRT and (b) VMAT plans for malignant glioma. The dose prescribed to the
planning target volume (PTV) (red contour) is 60 Gy in 30 fractions. The 95% isodose (green line) is encompassing most of the
PTV. There is compromise of PTV coverage to allow sparing of the optic nerves (dark blue contour) and brain stem (pink
contour). Figures courtesy of Dr R Shaffer. Reprinted from Int J Radiat Oncology Biol Phys, Vol. 76, No.4, Shaffer R, Nichol AM,
Vollans E, Fong M, Nakano S, Moiseenko V et al. A comparison of volumetric modulated arc therapy and conventional intensity-
modulated radiotherapy for frontal and temporal high-grade gliomas, pp. 1177-1184, Copyright 2010, with permission from
Elsevier [133].
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Table 6. Comparative planning studies in breast cancer
Paper [ref] VMAT
commercial system
Number of
patients
Site Comparison PTV OAR MU per fraction Treatment time per
fraction
Qiu
et al [142]
Rapidarc
8 Breast (partial
breast
radiotherapy)
3D-CRT (non
coplanar, 4–5F) vs
VMAT (modified
partial arc)
Similar PTV coverage.
VMAT slightly better than
3D-CRT at conformity (not
statistically significant)
VMAT better than 3D-CRT at
sparing ipsilateral normal
breast tissue, ipsilateral lung
VMAT, 488.6;
3D-CRT,
634.1
VMAT, 1.21 min;
3D-CRT,
6.3 min
Popescu
et al [143]
Predecessor
to RapidArc
5 Breast (+ regional
nodes including
internal
mammary
nodes)
3D-CRT vs IMRT
(9F,SW) vs VMAT
(2 partial arcs)
Similar PTV coverage,
homogeneity, conformity
VMAT better than IMRT and
3D-CRT at sparing heart and
ipsilateral lung (low and
intermediate doses),
contralateral breast (mean
dose). VMAT – lower mean
dose to healthy tissue but
higher V5Gy compared with
3D-CRT and IMRT
VMAT, 862;
IMRT, 1254;
3D-CRT,489
VMAT, 3.9 min;
IMRT, 8.8 min;
3D-CRT, 5 min
Johansen
et al [144]
RapidArc
8 Breast (chest wall
and nodes
including internal
mammary nodes)
CRT (4F) vs IMRT
(7F,SW) vs VMAT
Similar PTV coverage. VMAT
and IMRT better than CRT
for conformity. VMAT better
than IMRT and CRT for
homogeneity
VMAT and IMRT better than
CRT at sparing ipsilateral
lung. CRT – lowest doses to
contralateral lung. VMAT –
lowest doses to
contralateral breast
Nicolini
et al [145]
RapidArc
10 Breast (Bilateral,
SIB to tumour
bed)
IMRT (12F,SW)
vs VMAT (DA)
Similar PTV coverage. VMAT
better than IMRT at
homogeneity
VMAT better than IMRT at
sparing heart and lungs
(medium-high dose level)
(for lungs, IMRT better at
sparing at low dose levels).
VMAT – higher mean and
integral dose to healthy
tissue
VMAT, 796;
IMRT, 1398
VMAT, 3 min;
IMRT, 11.5 min
VMAT, volumetric modulated arc therapy; PTV, planning target volume; OAR, organs at risk; MU, monitor units; 3D-CRT, three-dimensional conformal radiotherapy; IMRT, intensity
modulated radiotherapy; 4F, four field; 5F, five field; 7F, seven field; 9F, nine field; 12F, twelve field; SW, sliding window; SS, step-and-shoot; V5Gy, volume receiving >5Gy;
SIB, simultaneous integrated boost.
R
e
vie
w
a
rticle
:
A
re
vie
w
o
f
vo
lu
m
e
tric
m
o
d
u
la
te
d
a
rc
th
e
ra
p
y
T
h
e
B
ritish
Jo
u
rn
a
l
o
f
R
a
d
io
lo
g
y,
N
o
ve
m
b
e
r
2
0
1
1
9
8
7
difference was seen in cardiac sparing between the two
techniques. This study did not include conventional CRT
techniques in their comparison, which would have
resulted in lower doses to healthy tissue and OAR
distant to the target volume (e.g. breast). This needs to be
balanced against the potential of IMRT and VMAT to
improve sparing of OARs within or close to the target
volumes (e.g. lung). The authors discuss that there may
be a significant role for smaller radiation fields in the
treatment of this disease, using involved nodal radio-
therapy (INRT) as opposed to involved field radio-
therapy (IFRT). These two strategies were also compared
using both techniques in this study and there was a
universally significant reduction in OAR doses with
INRT compared with IFRT.
Intra-abdominal tumours
VMAT has also been evaluated in intra-abdominal
malignancy. Eppinga et al [149] evaluated VMAT in a
planning study for advanced pancreatic cancer. VMAT
plans achieved better conformity and OAR sparing (left
kidney, liver, stomach, small bowel and duodenum)
compared with fixed field IMRT (SW). Llacer-Moscardo
et al [150] performed a dosimetric feasibility study of
VMAT in retroperitoneal sarcoma and found acceptable
target volume coverage and OAR sparing. Benthuysen
et al [151] evaluated VMAT in distal oesophageal cancers
and found comparable PTV coverage and OAR sparing
to fixed field IMRT with a 42–67% reduction in MU, but
greater low dose radiation to the body (V5 Gy 18%
greater for VMAT plans). Hawkins et al [152] compared
VMAT with 4-field CRT in 10 patient datasets with
locally advanced or inoperable distal oesophageal
cancers. They found improved OAR sparing (V30 Gy
to heart 31% vs 55%) and improved PTV conformity with
VMAT. Bignardi et al [153] conducted a planning study
to compare VMAT with conventional CRT and nine-field
fixed field IMRT (SW) in SBRT for abdominal metastatic
lymph nodes (solitary metastasis or oligometastatic dis-
ease). The conventional technique used 428 static beams
or 324 conformal short arcs. The results showed VMAT
achieved the best PTV coverage (V95%, 90.2% (VMAT) vs
82.5% (CRT) vs 84.5% (IMRT)) and slightly superior dose
conformity. OAR sparing was better with IMRT and
VMAT compared with CRT. Scorsetti et al [154] reported
on early clinical results with VMAT (RapidArc, Varian)
in the treatment of primary or metastatic tumours at
abdominal sites, which showed promising results in terms
of local control and acute toxicity rates. An important
factor to consider in intra-abdominal radiotherapy is the
effect of intrafraction motion, which can reduce the
accuracy of treatment, and methods to account for this
should be considered.
Paediatric cases
There has been some debate on the use of IMRT
techniques for paediatric cases owing to the concerns of a
potential increase in radiation-induced secondary malig-
nancy. IMRT plans typically use a larger number of MU
and require longer treatment delivery times compared
with conventional radiotherapy techniques, which can
result in higher low dose radiation to normal tissues.
VMAT techniques could theoretically lower the risk
because VMAT plans generally require fewer MU and
shorter treatment times compared with fixed field IMRT.
The shorter treatment time could also be beneficial in
cases where there may be issues with the treatment
position causing patient discomfort or difficulties with
airway access where general anaesthesia is required. One
such example is craniospinal irradiation (CSI), which is
an important part of the treatment of paediatric tumours,
such as medulloblastoma. In general, patients are treated
in the prone position because this allows better visuali-
sation of the matching field junctions between the cranial
and spinal fields, although several institutions have now
adopted the supine technique as this is more comfortable
for patients. Two recent studies evaluating VMAT in this
setting have been recently published. Fogliata et al [155]
reported on their experience using VMAT to deliver CSI
in five patients from five different institutions (age range,
7–45 years). They found that VMAT could achieve highly
conformal plans with acceptably low doses to OARs. A
further benefit of VMAT (or IMRT technique) is the ability
to treat the entire target volume without the need for
matching field junctions, which is required in conven-
tional techniques. This could reduce the risk of over
dosage at the junction that could lead to increased risk of
radiation myelitis or insufficient dosage that could poten-
tially increase the risk of treatment failure. Another study
by Lee et al [156] compared VMAT with conventional
radiotherapy techniques for CSI in 5 patient datasets
(3 patients were under 16 years old) and report improved
target volume conformity and heterogeneity with VMAT,
as well as significantly lower doses to OARs (heart,
oesophagus, optic nerve and lens). V15 Gy and V10 Gy to
the body were reduced in the VMAT plans but V2 Gy and
V5 Gy were higher with VMAT, with a higher integral
dose to non-PTV body volume in 4 of the 5 patients.
A planning study by Shaffer et al [157] evaluated
single arc VMAT in 8 paediatric cases with retroper-
itoneal tumours in comparison with 7-field fixed field
IMRT (SW), 3D-CRT and a parallel-opposed pair (POP)
plan. VMAT and IMRT were able to achieve improved
conformity and lower dose to the liver compared with
3D-CRT and POP, but at the expense of greater MU
usage. VMAT has also been evaluated in the setting of
total body irradiation (TBI), which is part of the pre-
conditioning regimen used in haematological malignan-
cies prior to bone marrow transplantation. A significant
number of these patients will include children and
young adults; therefore, the priority should be placed
on reducing the rates of late toxicity and morbidity as a
result of radiotherapy. Two recent planning studies
evaluating VMAT in this setting have been published.
Fogliata et al [158] reported on the feasibility of using
VMAT to deliver TBI, which achieved satisfactory target
coverage and acceptably low doses to the OARs (median
dose for OARs ranged from 2.3 Gy for the oral cavity to
7.3 Gy for the bowels). Aydogan et al [159] compared
VMAT with fixed field IMRT and tomotherapy and
found comparable dose distributions between the tech-
niques. With respect to OAR sparing, VMAT achieved
lower median doses to the heart, liver and bowel
compared with fixed field IMRT and tomotherapy, and
M Teoh, C H Clark, K Wood et al
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Table 7. Comparative planning studies in other tumour sites (lymphoma, intra-abdominal malignancies and paediatric tumours)
Paper [ref] VMAT
commercial
system
Number of
patients
Site and type Comparison PTV OAR MU per fraction Treatment time per
fraction
Weber
et al [148]
RapidArc
10 Stage I, II
Hodgkins
lymphoma
(IFRT vs INRT)
IMRT (9F,SW) vs
VMAT (SA)
IFRT: similar PTV coverage,
homogeneity; VMAT
slightly better than IMRT
for conformity. INRT: VMAT
slightly better than for PTV
coverage (not statistically
significant). No difference
in homogeneity
VMAT better than IMRT at
sparing lung (mid-dose level),
breast (high to mid-dose
level). No difference in cardiac
sparing. VMAT – lower integral
dose to body compared with
IMRT
IMRT, 102021255;
VMAT,
3672376
Eppinga
et al [149]
RapidArc
10 Pancreas IMRT (5F,SW) vs
VMAT (DA)
Similar PTV coverage. VMAT
better than IMRT for
conformity
VMAT better than IMRT for
OAR sparing (kidneys, liver,
stomach, bowel and
duodenum)
VMAT, 561;
IMRT, 800
(Beam-on time)
VMAT, less than
3 min; IMRT,
8 min
Benthuysen
et al [151]
14 Oesophagus IMRT (7F) vs VMAT
(SA or DA)
Similar PTV coverage.
IMRT slightly better
than VMAT for
homogeneity
Similar OAR sparing. VMAT –
higher body V5Gy compared
to IMRT
VMAT (SA), 401;
VMAT (DA),
449.5; IMRT,
782
Hawkins
et al [152]
10 Oesophagus 3D-CRT (4F)
vs VMAT
Similar PTV coverage. VMAT
better than 3D-CRT for
conformity
VMAT better than IMRT at
sparing heart. VMAT –
higher volumes of lung
receiving low dose (V5Gy,
V10Gy). No difference in
V20Gy and mean lung dose
VMAT, 260;
IMRT, 320
VMAT,
1.121.47 min;
IMRT, 3.25 min
Bignardi
et al [153]
RapidArc
14 Abdominal
metastases
SBRT 45Gy in
6 fractions
CRT (428 static
beams, or 324
conformal short
arcs) vs IMRT
(9F,SW) vs
VMAT (SA)
VMAT better than CRT and
IMRT for PTV coverage
(V95%) and slightly better
for conformity
VMAT and IMRT better than
CRT for OAR sparing
VMAT, 2186;
IMRT, 2583;
CRT, 1554
VMAT, 3.7 min;
IMRT, 10.6 min;
CRT, 6.3 min
Lee et al
[156]
SmartArc
5 Craniospinal
radiotherapy
Conventional
vs VMAT
VMAT better than
conventional for
conformity and
homogeneity
VMAT better than conventional
at sparing heart, thyroid,
oesophagus, lenses, optic
nerves, eyes. VMAT – higher
mean doses to kidneys, liver.
VMAT – higher mean lung
dose but lower V20Gy. VMAT
– lower body V15Gy and
V10Gy, but higher V5Gy
and V2Gy
VMAT, 622.4;
conventional,
600.4
VMAT, 9.42 min;
conventional,
15 min
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lower median doses to lungs, kidneys, eyes and oral
cavity compared with tomotherapy. Treatment delivery
time with VMAT was reduced to approximately 18 min
compared with 45 min with fixed field IMRT.
A summary of comparative planning studies in the
tumour sites/types as specified above is presented in
Table 7. An example of dose distributions achieved with
VMAT and fixed field IMRT in paediatric retroperitoneal
tumours is illustrated in Figure 4.
Conclusion
VMAT is a new radiation technique that combines the
ability to achieve highly conformal dose distributions
with highly efficient treatment delivery. Most of the
published data in the literature are dosimetric planning
studies with limited clinical outcome data. However,
VMAT is still a novel technology and as increasing
numbers of patients are treated with this technique, more
clinical data will emerge. Most of the planning studies in
various tumour sites have compared VMAT with either
fixed field IMRT or conventional CRT techniques. VMAT
has clear superiority over conventional CRT with regard
to improving dose conformity and OAR sparing.
However, the distinction between VMAT and fixed field
IMRT is less clear. The data suggests that for most
tumour sites VMAT and fixed field IMRT will produce
largely equivalent target volume coverage, dose con-
formity and homogeneity. The absolute difference in
dosimetric parameters reported as statistically significant
in some of the planning studies is relatively small and
may not be clinically significant. Similarly with OAR
sparing, some planning studies have reported equivalent
results between VMAT and fixed field IMRT. However,
for sites such as prostate or cervical cancer, some studies
have reported significant improvement in OAR sparing
with VMAT. The similarities between VMAT and fixed
field IMRT are not surprising given that VMAT is
essentially an alternative form of IMRT. The significant
difference between VMAT and fixed field IMRT is the
reduction in MU and treatment delivery time, which was
an almost universal finding in all the planning studies.
There are inherent limitations with these planning
studies. Even if the same strict planning objectives and
calculation algorithms were used, it is extremely difficult
to completely eliminate planner bias especially if multi-
ple planners are involved in the process. Direct compar-
isons between different studies are not possible because
of significant differences in target volume definitions,
dose prescription and treatment schedules. Radiation
techniques also vary between the studies, for example in
the number of fields and arcs used in the fixed field IMRT
and VMAT plans, and IMRT technique (SW or SS). As a
result, it is not surprising that the results on PTV coverage
and OAR sparing can appear conflicting between the
studies.
A major source of concern with VMAT and IMRT is
the increase in low dose radiation to surrounding normal
tissue, which potentially increases the risk of secondary
malignancy. It is estimated that the incidence of secondary
malignancies could almost double with IMRT compared
with conventional techniques (from 1% to 1.75% for
patients surviving 10 years) [21]. Although the theoreticalPa
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risk of secondary malignancy induction with VMAT
should be lower as VMAT generally uses fewer MU
compared with conventional fixed field IMRT, this could
be counteracted by the increase of normal tissue volume
receiving low dose radiation, which has been seen in a
number of studies [9, 129, 132, 143, 156]. Longer follow-up
of patients treated with these techniques will be required
to accurately quantify this risk.
Finally, although there is evidence to show that VMAT
has a definite place in the treatment of many tumours, it
cannot be considered the universal solution for all clinical
scenarios. Each case must be evaluated on an individual
basis to select the most appropriate radiation technique
that will give optimal results.
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